valproic acid has been researched along with Migraine Disorders in 223 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Migraine Disorders: A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sodium valproate and ibuprofen are drugs with known efficacy in the treatment of headache associated with acute migraine attacks." | 5.51 | Intravenous ibuprofen versus sodium valproate in acute migraine attacks in the emergency department: A randomized clinical trial. ( Akbas, I; Ceylan, M; Dogruyol, S; Gur, STA; Kocak, AO; Kocak, MB; Tekyol, D, 2022) |
| " Compared to other active drugs, it only showed a lower significant effect compared with granisetron regarding headache change while it showed significantly higher effects only with placebo in both rescue medication needs and headache-free symptoms and valproate in only rescue medication need." | 5.41 | The efficacy and safety of metoclopramide in relieving acute migraine attacks compared with other anti-migraine drugs: a systematic review and network meta-analysis of randomized controlled trials. ( Abd-ElGawad, M; Abdelhay, HM; Abdelmonem, H; Abdelwadoud, GT; Ahmed, AE; Al-Dardery, NM; Alhosini, ANM; Kamel, MA; Mohamed, SW, 2023) |
| "This review was designated to evaluate the efficacy of parenteral ketorolac in treating acute migraine headache." | 5.22 | Efficacy of ketorolac in the treatment of acute migraine attack: A systematic review and meta-analysis. ( Abu Bakar, MA; Baharuddin, KA; Norhayati, MN; Nurathirah, MN; Yazid, MB, 2022) |
| "Comparison of the change in median VAS scores over 60 minutes revealed that sodium valproate was significantly less effective than prochlorperazine in reducing pain or nausea (P <." | 5.10 | Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial. ( French, T; Miller, S; Riffenburgh, RH; Tanen, DA, 2003) |
| " On the other hand, patients with divalproex exhibited significantly higher risk of nausea compared to those with placebo, topiramate, propranolol, gabapentin and amitriptyline." | 4.95 | Unveiling the relative efficacy, safety and tolerability of prophylactic medications for migraine: pairwise and network-meta analysis. ( He, A; Li, C; Song, D; Zhang, L, 2017) |
| "A MEDLINE (1967-June 2007) and bibliographic search of the English-language literature was conducted using the search terms valproic acid and migraine disorders." | 4.84 | Use of intravenous valproic acid for acute migraine. ( Foraker, KC; Frazee, LA, 2008) |
| "At present there are three compounds in clinical trials in patients with epilepsy that can be regarded as second-generation VPA: valproyl glycinamide, 3-methylbutanamide or isovaleramide and SPD421 (DP-VPA)." | 4.82 | New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet? ( Bialer, M; Isoherranen, N; Yagen, B, 2003) |
| "Shire is developing DP-VPA, a prodrug of valproic acid (VPA) licensed from D-Pharm, for the potential treatment of severe forms of epilepsy, including status epilepticus, acute repetitive seizures in children and possibly manic depression and migraine [242649], [385958]; the drug is also being developed for bipolar disorder and migraine prophylaxis [385862]." | 4.81 | DP-VPA D-Pharm. ( Labiner, DM, 2002) |
| " For the acute treatment of migraine attacks or tension-type headache, ibuprofen (10 mg per kg body weight) or acetaminophen (15 mg per kg body weight) are recommended with highest evidence, intranasal sumatriptan (10 to 20 mg) can be given as second choice." | 4.81 | [Treatment of idiopathic headache in childhood - recommendations of the German Migraine and Headache Society (DMKG)]. ( Evers, S; Gerber, WD; Naumann, E; Pothmann, R; Uberall, M, 2002) |
| " In a post-hoc comparison, responders to levetiracetam had significantly less migraine attacks at baseline and had significantly more often migraine with aura." | 4.12 | Levetiracetam in the prophylactic treatment of episodic migraine: A prospective open label study. ( Evers, S; Frese, A; Husstedt, IW; Marziniak, M; Summ, O, 2022) |
| "Beta-blockers are effective for migraine attack prophylaxis but are associated with dizziness and fatigue and are contraindicated in patients with certain co-morbidities, including asthma, congestive heart failure, and abnormal cardiac rhythms." | 3.01 | Non-CGRP Antagonist/Non-Triptan Options for Migraine Disease Treatment: Clinical Considerations. ( Ahmadzadeh, S; Bocklud, BE; Corley, SC; Granier, MA; Ingram, EE; Kaye, AD; Neuchat, EE; Shekoohi, S, 2023) |
| "However, in contrast to ordinary migraine, vestibular migraine patients have distinct characteristics, and the detailed treatment strategy for vestibular migraine is different and more challenging than ordinary migraine treatment." | 3.01 | Network Meta-analysis of Different Treatments for Vestibular Migraine. ( Chen, JJ; Chen, TY; Chen, YW; Hsu, CW; Stubbs, B; Su, KP; Tseng, PT; Tu, YK; Wu, YC; Zeng, BS; Zeng, BY, 2023) |
| "The characteristics of migraine, including frequency, severity, duration of the attacks, and the number of painkillers taken per month, were monthly recorded in each visit." | 3.01 | Comparative study of magnesium, sodium valproate, and concurrent magnesium-sodium valproate therapy in the prevention of migraine headaches: a randomized controlled double-blind trial. ( Hejazi, SA; Khani, S; Sharifipour, E; Yaghoubi, M, 2021) |
| "The mean number of migraine attacks and days per month was 1." | 3.01 | The efficacy of magnesium oxide and sodium valproate in prevention of migraine headache: a randomized, controlled, double-blind, crossover study. ( Heidari, M; Karimi, N; Razian, A, 2021) |
| "The frequency of migraine attacks significantly reduced compared to baseline in cinnarizine (difference: -8." | 2.94 | Cinnarizine and sodium valproate as the preventive agents of pediatric migraine: A randomized double-blind placebo-controlled trial. ( Agah, E; Amanat, M; Ashrafi, MR; Azizi Malamiri, R; Eshaghi, H; Fashandaky, F; Heidari, M; Ramezani, M; Salehi, M; Tavasoli, AR; Togha, M, 2020) |
| "Migraine is not curable, but preventive treatments are usually used to decrease the intensity and frequency of headache attacks." | 2.84 | Levetiracetam in Compare to Sodium Valproate for Prophylaxis in Chronic Migraine Headache: A Randomized Double-Blind Clinical Trial. ( Ghadikolaei, HS; Kashipazha, D; Siavashi, M, 2017) |
| "Melatonin may prove to be an efficient substitute for sodium valproate, as a chronic migraine prophylaxis." | 2.84 | Use of melatonin versus valproic acid in prophylaxis of migraine patients: A double-blind randomized clinical trial. ( Abdolrazaghnejad, A; Ebrahimi-Monfared, M; Faraji, F; Mohammadbeigi, A; Sharafkhah, M, 2017) |
| "Cinnarizine has demonstrated encouraging potential in preventing the attacks of migraine." | 2.82 | Application of cinnarizine in migraine prevention: A systematic review and meta-analysis. ( Akbari, Z; Ardestani, PM; Gholampour, M; Kouhanjani, MF; Nemati, H; Sarvipour, N; Shafie'ei, M; Shekouh, D, 2022) |
| " There was no significant difference in the occurrence of common adverse drug reactions, such as drowsiness and fatigue, between the melatonin group and the comparison groups." | 2.82 | Efficacy and Safety of Melatonin as Prophylaxis for Migraine in Adults: A Meta-analysis. ( Jena, M; Maiti, R; Mishra, A; Mishra, BR; Puliappadamb, HM, 2022) |
| "Migraine is a common primary headache disorder diagnosed in the emergency department (ED)." | 2.82 | Sodium Valproate Versus Dopamine Antagonists for Acute Migraine in the Emergency Department: A Systematic Review. ( Cheng, W; Cortel-LeBlanc, M; Nath, A; Patel, D; Perry, JJ; Viau, JA, 2022) |
| "Migraine is a common and incapacitating neurologic disorder manifesting with episodic moderate to a severe headache and other symptoms such as photophobia, phonophobia, nausea, and vomiting." | 2.80 | Intravenous Valproate versus Subcutaneous Sumatriptan in Acute Migraine Attack. ( Ghaderibarmi, F; Tavakkoli, N; Togha, M, 2015) |
| "Three hundred migraineurs having >4 attacks monthly were randomized into DVA-ER or AMT." | 2.78 | Amitriptyline vs divalproate in migraine prophylaxis: a randomized controlled trial. ( Bhoi, SK; Kalita, J; Misra, UK, 2013) |
| "Participants completed Migraine Disability Assessment (MIDAS) and Headache Impact Test (HIT-6) questionnaires before and after treatment." | 2.78 | The effects of cinnarizine versus sodium valproate in migraine prophylaxis. ( Bostani, A; Moradian, N; Rajabi, A; Razazian, N; Rezaei, M, 2013) |
| "We report the predictors of allodynia in migraine and the effect of divalproate or amitriptyline in alleviating allodynia." | 2.78 | Allodynia in migraine: clinical observation and role of prophylactic therapy. ( Bhoi, SK; Kalita, J; Misra, UK, 2013) |
| "Topiramate and valproate were administered at 50 mg/day and 400 mg/day, respectively, during the follow-up period." | 2.77 | A comparative study of the effects of low-dose topiramate versus sodium valproate in migraine prophylaxis. ( Afshari, D; Rafizadeh, S; Rezaei, M, 2012) |
| "The diagnosis of migraine was based on the International Headache Society classification criteria." | 2.76 | Intravenous sodium valproate aborts migraine headaches rapidly. ( Bowirrat, A; Saleh, SA; Shahien, R, 2011) |
| "Topiramate selectively was prescribed to 69 patients and DVP selectively to 51." | 2.76 | Topiramate vs divalproex sodium in the preventive treatment of migraine: a prospective "real-world" study. ( Jevoux, CC; Krymchantowski, AV, 2011) |
| "The propranolol dosage was adjusted to 2 mg/kg/day and the sodium valproate dosage to 15 mg/kg/day, after the first follow-up visit." | 2.75 | A randomized trial of propranolol versus sodium valproate for the prophylaxis of migraine in pediatric patients. ( Bidabadi, E; Mashouf, M, 2010) |
| " Four patients experienced relapse with a decreased dosage of valproate." | 2.74 | Effective prophylactic therapy for cyclic vomiting syndrome in children using valproate. ( Amakata, K; Fujii, Y; Hikita, T; Kaga, F; Kaneko, S; Kodama, H; Nakamoto, N; Ogita, K; Yanagawa, Y, 2009) |
| " Subjects from the previous trial who had experienced serious adverse events possibly or probably related to study drug were excluded." | 2.74 | Safety and tolerability of divalproex sodium extended-release in the prophylaxis of migraine headaches: results of an open-label extension trial in adolescents. ( Abi-Saab, WM; Apostol, G; Laforet, GA; Olson, E; Pakalnis, A; Robieson, WZ; Saltarelli, M, 2009) |
| " Safety was evaluated by adverse event collection, laboratory assessments, physical and neurological examinations, vital signs, electrocardiograms, the Udvalg for Kliniske Undersøgelser Side Effect Rating Scale, the Wechsler Abbreviated Scale of Intelligence, and the Behavioral Assessment Scale for Children." | 2.74 | Divalproex sodium extended-release for the prophylaxis of migraine headache in adolescents: results of a stand-alone, long-term open-label safety study. ( Abi-Saab, WM; Apostol, G; Fugate, JM; Laforet, GA; Lewis, DW; Robieson, WZ; Saltarelli, MD, 2009) |
| "For treatment and control of the migraine, in patients with normal encephalogram, propranolol with tricyclic antidepressive drugs advised and for abnormal encephalogram sodium valprovate can be the better treatment for management and reduction of headache attacks." | 2.74 | Comparison of treatment effect of sodium valproate, propranolol and tricyclic antidepressants in migraine. ( Abolfazl, MB; Keyvan, G, 2009) |
| "Divalproex sodium has been approved for migraine prophylaxis in adults, and previous uncontrolled data suggest divalproex sodium may be effective in preventing migraine in children and adolescents with acceptable tolerability." | 2.73 | Divalproex extended-release in adolescent migraine prophylaxis: results of a randomized, double-blind, placebo-controlled study. ( Abi-Saab, WM; Apostol, G; Cady, RK; Laforet, GA; Olson, E; Robieson, WZ; Saltarelli, M, 2008) |
| "Frequent migraine headaches can have a significant impact on disability, prompting the need for early recognition and treatment." | 2.73 | Comparison of the effectiveness of topiramate and sodium valproate in pediatric migraine. ( Oztürk, A; Unalp, A; Uran, N, 2008) |
| "Thirty-six patients established on migraine prophylaxis were administered 500 mg sodium valproate intravenously against acute migraine attacks." | 2.73 | Safety and efficacy of intravenous sodium valproate in the treatment of acute migraine. ( Marková, J; Mastík, J; Waberzinek, G, 2007) |
| "Histamine has a selective affinity for H3-receptors and it may specifically inhibit the neurogenic edema response involved in migraine pathophysiology." | 2.73 | Subcutaneous histamine versus sodium valproate in migraine prophylaxis: a randomized, controlled, double-blind study. ( Barreto-Vizcaíno, S; Garcia-Solorzano, A; Isais-Millán, R; López-Blanca, C; Membrila-Maldonado, M; Millán-Guerrero, RO; Muñoz-Solis, R; Rivera-Castaño, L, 2007) |
| "A total of 64 patients with migraine headache, aged 14 to 57 years, were randomly allocated to the 2 treatment groups." | 2.72 | Comparison of the effect of topiramate and sodium valporate in migraine prevention: a randomized blinded crossover study. ( Ashtary, F; Ghorbani, A; Janghorbani, M; Nasr, V; Shaygannejad, V; Zakizade, N, 2006) |
| "Among headache types, unclassifiable chronic headache segregated from all other classified headaches in terms of poor response." | 2.71 | Treatment of primary headache disorders with intravenous valproate: initial outpatient experience. ( Rybicki, LA; Stillman, MJ; Zajac, D, 2004) |
| "Both drugs were effective in acute migraine attacks with a trend in favor of iLAS." | 2.71 | Comparison of intravenous valproate with intravenous lysine-acetylsalicylic acid in acute migraine attacks. ( Diener, HC; Leniger, T; Limmroth, V; Pageler, L; Stude, P, 2005) |
| "To examine the metabolic effects of three divalproex dosing regimens in patients with migraine." | 2.71 | Effect of divalproex on metabolic parameters is dose related in migraine prophylaxis. ( Giordano, S; Green, MW; Jafari, M; Jiang, P; Smith, TB, 2005) |
| "Treatment of chronic daily headache/transformed migraine is challenging, especially when it is complicated by overuse of analgesics, triptans, or both." | 2.70 | Intravenous valproate sodium in the treatment of daily headache. ( Karpitskiy, VV; Schwartz, TH; Sohn, RS, 2002) |
| "Fifteen children with migraine according to International Headache Society criteria were included in the study." | 2.70 | Sodium valproate prophylaxis in childhood migraine. ( Erermis, S; Erhan, E; Oksel, F; Serdaroglu, G; Tekgul, H; Tutuncuoglu, S; Uyar, M, 2002) |
| "The frequency of migraine attacks was significantly reduced in group 1 from 3." | 2.70 | Valproic acid is effective in migraine prophylaxis at low serum levels: a prospective open-label study. ( Arnold, G; Clauss, M; Dreier, JP; Einhäupl, KM; Kinze, S; Reuter, U; Wolf, T, 2001) |
| "We examined the effect of standard migraine prophylaxis with sodium valproate on repeated measures of occipital excitability using transcranial magnetic stimulation (TMS)." | 2.70 | Visual cortex excitability in migraine before and after valproate prophylaxis: a pilot study using TMS. ( Chronicle, EP; Koehler, PJ; Mulleners, WM; Vredeveld, JW, 2002) |
| "Subjects with more than two migraine headache attacks during a 4-week baseline were randomly assigned in a 1:1 ratio at each center to receive either extended-release divalproex sodium or matching placebo once daily for 12 weeks." | 2.70 | A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. ( Carlson, HA; Collins, SD; Deaton, R; Freitag, FG; Goldstein, J; Mathew, N; Saper, J; Silberstein, S; Sommerville, K; Winner, PK, 2002) |
| "We studied the incidence of headache relief in our patients with migraine aged 16 years and younger treated with divalproex sodium prophylactically at our institution from July 1996 to December 1998 to determine medication dosage used, concomitant headache medications, and possible adverse effects." | 2.69 | The efficacy of divalproex sodium in the prophylactic treatment of children with migraine. ( Brown, WD; Caruso, JM; Exil, G; Gascon, GG, 2000) |
| "During the treatment phase, the mean migraine headache frequency per 4 weeks was 3." | 2.68 | Migraine prophylaxis with divalproex. ( Deaton, RL; Markley, HG; Mathew, NT; Rankin, L; Rapoport, AM; Saper, JR; Silber, CJ; Silberstein, SD; Solomon, S, 1995) |
| "Sixty percent of migraineurs had a 75% or more improvement in the number of headache days under sodium valproate, most of the remaining attacks being less severe." | 2.68 | Sodium valproate in severe migraine and tension-type headache: an open study of long-term efficacy and correlation with blood levels. ( Bastings, E; Lenaerts, M; Schoenen, J; Sianard, J, 1996) |
| "Patients with two or more migraine attacks during the baseline were randomized to receive a DVPX daily dose of 500, 1000, or 1500 mg, or to placebo." | 2.68 | Divalproex sodium in migraine prophylaxis: a dose-controlled study. ( Klapper, J, 1997) |
| "Propranolol was titrated to 180 mg/d in 28 patients, to 240 mg/d in 1, and downward in 3." | 2.68 | A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without aura. ( Kaniecki, RG, 1997) |
| "We included 43 patients with migraine without aura in a triple-blind, placebo- and dose-controlled, crossover study of the prophylactic effect of slow-release sodium valproate; 34 patients completed the trial." | 2.67 | Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. ( Brinck, T; Jensen, R; Olesen, J, 1994) |
| "Many parallel-group studies of migraine prophylaxis using valproate medications were reported in recent decades." | 2.66 | The efficacy and safety of valproate medications for migraine in adults: a meta-analysis. ( Cui, XY; Li, X; Liu, J; Sun, SM; Wu, QY; Zhang, JF, 2020) |
| "Pediatric migraine is a common, chronic, and disabling neurological disorder in children and adolescents." | 2.66 | Intravenous Migraine Treatment in Children and Adolescents. ( Hershey, AD; Kabbouche, M; Maconochie, I; Murphy, B; Qaiser, S; Werner, K, 2020) |
| "Propranolol was comparable to other medications known to be effective including flunarizine, topiramate and valproate." | 2.61 | Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis. ( Hayashino, Y; Jackson, JL; Jackson, W; Kuriyama, A; Kuwatsuka, Y; Nickoloff, S; Storch, D; Zhang, ZJ, 2019) |
| "Migraine is a disabling and prevalent condition that affects the pediatric and adolescent population." | 2.58 | The Changing Landscape of Pediatric Migraine Therapy: A Review. ( Patterson-Gentile, C; Szperka, CL, 2018) |
| "Many cases of valproate-associated parkinsonism have subsequently been published, but uncertainties remain concerning its prevalence, risk factors and prognosis." | 2.53 | Valproate-Associated Parkinsonism: A Critical Review of the Literature. ( Besag, FM; Bhatia, KP; Brugger, F, 2016) |
| "Individually, childhood epilepsy and migraine are two of the most common conditions seen in pediatric neurology." | 2.50 | Migraine and epilepsy in the pediatric population. ( Kossoff, EH; Oakley, CB, 2014) |
| "For patients with migraine, the pregnancy labeling of VPA will be changed from Category "D" to "X." | 2.50 | Risks of neurobehavioral teratogenicity associated with prenatal exposure to valproate monotherapy: a systematic review with regulatory repercussions. ( Gentile, S, 2014) |
| "We calculated MDs for Migraine Disability Assessment (MIDAS) scores." | 2.49 | Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. ( Chronicle, EP; Linde, M; McCrory, DC; Mulleners, WM, 2013) |
| "If a migraine attack takes more than 72 hours it is called status migrenosus (SM)." | 2.48 | [Treatment of prolonged migraine attack (status migrenosus)]. ( Artto, V; Kallela, M, 2012) |
| "Yet, migraine by itself is associated with an increased risk of suicidal ideation and behavior as well as with an increased risk of psychiatric disorders that facilitate the development of suicidal behavior." | 2.47 | Are antiepileptic drugs used in the treatment of migraine associated with an increased risk of suicidality? ( Kanner, AM, 2011) |
| "Severe, frequent and disabling migraine attacks, as well as those poorly responsive to acute care medication, require preventive treatment, which is often under-utilized." | 2.46 | Role of antiepileptic drugs as preventive agents for migraine. ( Rapoport, AM; Vikelis, M, 2010) |
| "Abdominal migraine is a commonly described migraine variant in children and young adults, but associations with Alice in Wonderland syndrome and lilliputian hallucinations are exceptional." | 2.46 | A migraine variant with abdominal colic and Alice in Wonderland syndrome: a case report and review. ( Hamed, SA, 2010) |
| " This once-a-day dosing formulation may increase compliance." | 2.46 | Valproate semisodium ER for migraine and cluster headache prophylaxis. ( Lovell, BV; Marmura, MJ, 2010) |
| "Monthly migraine frequency was used as the primary outcome measure in most of the studies." | 2.45 | Anticonvulsant drugs for pediatric migraine prevention: an evidence-based review. ( Bakola, E; Damigos, D; Mavreas, V; Skapinakis, P; Tzoufi, M, 2009) |
| "Pediatric migraine can cause a significant impact on quality of life." | 2.45 | [Antiepileptic drugs for the prevention of pediatric migraine]. ( Cuvellier, JC, 2009) |
| "These drugs can reduce the incidence of migraine attacks in the large clinical studies." | 2.45 | [Use of antiepileptic drugs for the preventive treatment of migraine]. ( Hamada, J, 2009) |
| "Women with untreated epilepsy are more likely to have irregular menstrual cycles than are nonepileptic controls, indicating that the disease itself plays a role in the etiology of these reproductive abnormalities." | 2.44 | Menstrual cycle dysfunction associated with neurologic and psychiatric disorders: their treatment in adolescents. ( Hayes, FJ; Joffe, H, 2008) |
| "Episodic migraine is a disabling painful disease that can affect the normal function of daily routine activities such as performance at work and school, and home and social relationships." | 2.44 | Medication overuse headache: awareness, detection and treatment. ( Rapoport, AM, 2008) |
| "A rationale for their use in migraine prophylaxis is the hypothesis that migraine and epilepsy share several common pathogenetic mechanisms." | 2.44 | Antiepileptic drugs in migraine: from clinical aspects to cellular mechanisms. ( Calabresi, P; Cupini, LM; Galletti, F; Rossi, C; Sarchielli, P, 2007) |
| "There is a general agreement now that migraine is not only a vascular phenomenon but also a genetically determined heterogenic ion-channelopathy resulting in cortical-spreading-depression-like events, the temporary impairment of antinociceptive structures of the brainstem and the activation of the trigeminal-vascular system." | 2.44 | GABAergic drugs for the treatment of migraine. ( Limmroth, V; Puppe, A, 2007) |
| "More severe migraines often require parenteral medications and sometimes intravenous fluids." | 2.43 | Migraine--diagnosis and treatment. ( Joubert, J, 2005) |
| "The mainstay of migraine treatment is pharmacotherapy." | 2.42 | The role of anticonvulsants in preventive migraine therapy. ( Corbo, J, 2003) |
| " These trials demonstrated a consistent pattern of efficacy and the delayed-release form improved tolerability while offering a twice-daily dosing schedule." | 2.42 | Divalproex sodium extended-release for the prophylaxis of migraine headache. ( Freitag, FG, 2003) |
| "Valproic acid has been used in the treatment of migraine headache for nearly 20 years." | 2.42 | Divalproex in the treatment of migraine. ( Freitag, FG, 2003) |
| "There are clear connections between migraine and psychiatric disorders and the attending physician should have them in mind." | 2.42 | [Migraine and psychiatric disorders]. ( Fasmer, OB; Oedegaard, KJ, 2004) |
| "The work on migraine can also have implications for the increasing number of additional neurological episodic disorders having the common denominator of channelopathy." | 2.41 | The impact of pharmacogenetics for migraine. ( Ferrari, MD; Frants, RR; Ophoff, RA; Roon, KI; van den Maagdenberg, AM, 2001) |
| "All papers on cluster headaches were reviewed according to preset criteria under the following headings: classification, epidemiology, aetiology, pathophysiology, and clinical features." | 2.41 | Cluster headache: review of the literature. ( Zakrzewska, JM, 2001) |
| "Headaches are a common entity in the ambulatory population." | 2.40 | Diagnosis, prophylaxis, and treatment of headaches in the athlete. ( Kaplan, B; Swain, RA, 1997) |
| "Basilar artery migraine is a rare headache characterized by attacks preceded and/or accompanied by transitory focal neurologic symptoms that point to dysfunction in the region irrigated by the basilar artery and its branches." | 2.40 | [Basilar artery migraine]. ( Díez-Tejedor, E; Moreno, MS, 1997) |
| "Management of migraine patients with or without aura must include appropriate medication to treat the attack and long-term preventive therapy, especially if the frequency of the attacks is greater than 2-4 per month." | 2.40 | Medical treatment of migraine: from mechanisms of action to contraindications. ( Annoni, JM; Higelin, F, 1998) |
| "Valproic acid was effective in all studies compared to placebo; one study confirmed an effect similar to propranolol." | 2.40 | [Valproic acid in prophylactic treatment of migraine]. ( Arnold, G; Einhäupl, KM, 1998) |
| "There was a reduction in the number of migraine attacks, and migraine duration and intensity were also reduced in some instances." | 2.39 | Divalproex sodium in headache: literature review and clinical guidelines. ( Silberstein, SD, 1996) |
| " New medications, such as sumatriptan, and new dosage forms of older medications, including dihydroergotamine, NSAIDs, and phenothiazines are available to treat acute attacks." | 2.38 | Therapeutic advances in migraine. ( Solomon, GD, 1993) |
| "This paper reviews the therapeutics of migraine in the context of the clinical problem and its prevalence." | 2.38 | The therapeutics of migraine. ( Welch, KM, 1993) |
| "The antimigraine efficacy of many drugs may be mediated less through their primary modes of action than through the common pathway of serotonergic transmission stabilization." | 2.38 | Acute and prophylactic treatment of migraine: practical approaches and pharmacologic rationale. ( Raskin, NH, 1993) |
| "Prophylactic treatments for migraine, such as topiramate or valproate, reduce the number of cortical spreading depression events in rodents." | 1.91 | Genome-wide DNA methylation analysis in an antimigraine-treated preclinical model of cortical spreading depolarization. ( Cormand, B; Cuenca-León, E; Fernàndez-Castillo, N; Kulis, M; Macaya, A; Martín-Subero, JI; Pozo-Rosich, P; Queirós, AC; Sintas, C; Vila-Pueyo, M, 2023) |
| "To compare pediatric migraine treatment efficacy in the emergency department before and after the implementation of a comprehensive migraine initiative, consisting of a standardized treatment protocol, provider educational series and standardized physician documentation template." | 1.56 | Comprehensive Migraine Initiative in the Pediatric Emergency Department Improves Treatment Outcomes. ( Oakley, CB; Skora, CE; Worden, LT, 2020) |
| "These results indicate that this repetitive dosing valproate sodium protocol is a safe and well-tolerated intervention for the treatment of chronic migraine resistant to oral medications." | 1.56 | Retrospective Chart Review of Intravenous Valproate Sodium as a Preventive Treatment for Patients With Chronic Migraine. ( Dapkus, L; Ehrlich, A; Levin, M; Riggins, N; Sawhney, H, 2020) |
| "For mild migraine, symptomatic treatment with high dose simple analgesics is suggested, while for moderate to severe migraines triptans or non-steroidal anti-inflammatory drugs, or both, should be administered following an individually tailored therapeutic strategy." | 1.51 | Consensus of the Hellenic Headache Society on the diagnosis and treatment of migraine. ( Arvaniti, C; Constantinidis, TS; Fakas, N; Giannouli, E; Kalamatas, T; Kararizou, E; Kouremenos, E; Mitsikostas, DD; Naoumis, D, 2019) |
| "Topiramate was more likely prescribed for those with comorbid headache or migraine (incident: 335 of 1251 [26." | 1.51 | Antiepileptic Drug Treatment Patterns in Women of Childbearing Age With Epilepsy. ( Faught, E; Fishman, J; Kalilani, L; Kim, H; Thurman, DJ, 2019) |
| "Comorbid migraine was present in 51." | 1.51 | Treatment effects and comorbid diseases in 58 patients with visual snow. ( Ferrari, MD; Onderwater, GLJ; Terwindt, GM; van Dongen, RM; Waaijer, LC, 2019) |
| "Consecutive migraineurs from a tertiary center to whom SD was prescribed as monotherapy from January 2017 until September 2018 were studied retrospectively." | 1.51 | Sodium Divalproate in Low Alternating Daily Doses for Migraine Prevention: A Retrospective Study. ( Jevoux, C; Krymchantowski, AG; Krymchantowski, AV, 2019) |
| "Migraine is a common disease with a high morbidity." | 1.48 | Valproate Plays a Protective Role against Migraine by Inhibiting Protein Kinase C Signalling in Nitroglycerin-treated Mice. ( Chen, N; Song, G; Wang, C; Wu, Q; Yi, L; Zhang, Z; Zou, Q, 2018) |
| "Lamotrigine was the most frequently initiated drug in psychiatry, in both boys and girls." | 1.48 | Utilization of Antiepileptic Medicines in Swedish Children and Adolescents with Different Diagnoses. ( Karlsson Lind, L; von Euler, M; Wettermark, B; Wide, K, 2018) |
| " This dosing strategy results in less serum concentration fluctuations, more consistent therapeutic effects, and less adverse effects." | 1.48 | Continuous Intravenous Valproate as Abortive Therapy for Pediatric Status Migrainosus. ( Baumann, RJ; Cook, AM; Stewart, AM; Toupin, DN; Zafar, MS, 2018) |
| "Migraine is a common and burdensome neurological condition which affects mainly female patients during their childbearing years." | 1.48 | Latest clinical recommendations on valproate use for migraine prophylaxis in women of childbearing age: overview from European Medicines Agency and European Headache Federation. ( Dogne, JM; Garcia Burgos, J; Girard, T; Martelletti, P; Straus, S; Vatzaki, E, 2018) |
| "Background The impact of adverse events (AEs) of antiepileptic drugs (AEDs) have an impact on compliance and dropouts." | 1.48 | Antiepileptic drugs in migraine and epilepsy: Who is at increased risk of adverse events? ( Bedetti, C; Calabresi, P; Caproni, S; Corbelli, I; Costa, C; Cupini, LM; Eusebi, P; Romoli, M; Sarchielli, P; Siliquini, S, 2018) |
| "Valproic acid (VPA) is a broad-spectrum antiepileptic drug (AED) that is also used for migraine prophylaxis, but its clinical use is limited by its side effect profile." | 1.43 | sec-Butylpropylacetamide (SPD) has antimigraine properties. ( Bates, EA; Bialer, M; Brennan, KC; Kaufmann, D; Saunders, GH; White, HS; Wilcox, K; Yagen, B, 2016) |
| "Background The development of novel migraine therapies has been slow, in part because of the small number of clinically relevant animal models." | 1.43 | The effects of acute and preventive migraine therapies in a mouse model of chronic migraine. ( Charles, A; McGuire, B; Pradhan, AA; Tarash, I; Tipton, AF, 2016) |
| "Valproic acid is a versatile antiepileptic drug that is often used in the acute care setting." | 1.43 | Pharmacokinetics and Clinical Utility of Valproic Acid Administered via Continuous Infusion. ( Albuja, AC; Baumann, RJ; Bensalem-Owen, M; Cook, AM; Kapoor, S; Mathias, S; Stewart, AM; Zafar, MS, 2016) |
| "Nitroglycerin (NTG) was employed to induce a migraine model in rats and the migraine animals were exposed to treatment of VPA of different doses." | 1.43 | Valproate ameliorates nitroglycerin-induced migraine in trigeminal nucleus caudalis in rats through inhibition of NF-кB. ( Li, Q; Li, Y; Qi, D; Yi, L; Zhang, L; Zhang, Q; Zhang, Z, 2016) |
| "Prophylactic therapy response varies in migraine patients." | 1.43 | Association of MDR1, CYP2D6, and CYP2C19 gene polymorphisms with prophylactic migraine treatment response. ( Ak, S; Atasayar, G; Can, FE; Cecener, G; Egeli, U; Eryilmaz, IE; Karli, N; Taskapilioglu, O; Tezcan, G; Tunca, B; Yildirim, O; Zarifoglu, M, 2016) |
| "BACKGROUND Migraine is a chronic disease that interferes with life quality and work productivity." | 1.43 | Valproate Attenuates Nitroglycerin-Induced Trigeminovascular Activation by Preserving Mitochondrial Function in a Rat Model of Migraine. ( Chen, N; Li, R; Liu, Y; Song, G; Zhang, Y; Zhang, Z, 2016) |
| "Many migraine sufferers use daily prophylactic therapy to reduce the frequency of their headache attacks." | 1.43 | Using a graphical risk tool to examine willingness to take migraine prophylactic medications. ( Golding, AN; Houle, TT; Turner, DP, 2016) |
| "Headaches are common in the pediatric population, and increase in prevalence with age." | 1.42 | Intravenous Sodium Valproate for Acute Pediatric Headache. ( Hansen, M; O'Brien, P; Sheridan, D; Sun, B, 2015) |
| "Magnesium sulfate has a short-lived vasodilatory effect and increased cortical blood volume in our experiment." | 1.42 | Cerebral reactivity in migraine patients measured with functional near-infrared spectroscopy. ( Danesh, A; Grothusen, J; Pourrezaei, K; Pourshoghi, A; Tabby, DS, 2015) |
| "Lamotrigine has a marked suppressive effect which correlates with its rather selective action on the migraine aura." | 1.37 | Migraine preventive drugs differentially affect cortical spreading depression in rat. ( Bogdanov, VB; Bogdanova, OV; Chauvel, V; Makarchuk, MY; Multon, S; Prodanov, D; Schoenen, J, 2011) |
| "Oxcarbazepine did not suppress spreading depression either after a single dose or after daily treatment for 5 weeks." | 1.37 | Oxcarbazepine does not suppress cortical spreading depression. ( Ayata, C; Dileköz, E; Hoffmann, U; Kudo, C, 2011) |
| "Acute confusional migraine (ACM) is a dramatic, rare manifestation of migraine described mostly for children and adolescents." | 1.36 | Acute confusional migraine in an adolescent: response to intravenous valproate. ( Avraham, SB; Har-Gil, M; Watemberg, N, 2010) |
| "Chronic migraine is an important public health problem." | 1.36 | Pharmacological prophylaxis of chronic migraine: a review of double-blind placebo-controlled trials. ( D'Amico, D, 2010) |
| "These findings indicate that: (a) migraine is the most frequent cause of headache in pediatric patients, (b) it has negative effects on school performance and daily activities, (c) the family history is important for making the diagnosis and (d) prophylaxis is significantly effective." | 1.36 | Profile of children with migraine. ( Aydin, M; Bozdag, S; Ertugrul, S; Kabakus, N, 2010) |
| "To describe the dose-concentration relationship of a continuous intravenous infusion of valproic acid (VPA) in pediatric patients when a dosing protocol is used." | 1.34 | Clinical utility of a continuous intravenous infusion of valproic acid in pediatric patients. ( Baumann, RJ; Cook, AM; Farzam, F; Kuhn, RJ; Lewis, DA; Taylor, LM, 2007) |
| "(6) Flunarizine also has documented efficacy, but this "hidden neuroleptic" can cause extrapyramidal disorders and weight gain." | 1.33 | Pharmacological prevention of migraine: to be considered case by case. ( , 2006) |
| "Adding a preventive medication to migraine management reduced the use of other migraine medications, as well as visits to physician offices and emergency departments." | 1.32 | Migraine preventive medication reduces resource utilization. ( Chmiel, JJ; Silberstein, SD; Winner, PK, 2003) |
| "They had previously undergone other migraine preventive treatment unsuccessfully." | 1.31 | Valproic acid in migraine prophylaxis of young patients. Three new reports. ( Capone, C; Faienza, C; Fusco, C; Pisani, F, 2002) |
| "The complex relationship between migraine and epilepsy is highlighted by the occurrence of a seizure during a migraine attack without aura." | 1.31 | Migraine-associated seizure: a case of reversible MRI abnormalities and persistent nondominant hemisphere syndrome. ( Dodick, DW; Friedenberg, S, 2000) |
| "In Study 1, 12 migraine with aura patients (MA), 12 age-matched migraine without aura patients (MO) and 12 age- and sex-matched headache-free control subjects (C) were compared using the metacontrast test." | 1.31 | Cortical hyperexcitability is cortical under-inhibition: evidence from a novel functional test of migraine patients. ( Chronicle, EP; Mulleners, WM; Palmer, JE; Rolan, P, 2000) |
| "Patients with migraines have typically been given one group of medications for abortive treatment and another for preventative." | 1.31 | Use of intravenous valproate sodium in status migraine. ( Norton, J, 2000) |
| "Seven patients had comorbid psychiatric disorders, whereas six patients had epilepsy (three rolandic, two generalized, and one indeterminate)." | 1.31 | Pediatric migraine prophylaxis with divalproex. ( Drake, ME; Greenberg, G; Pakalnis, A; Paolichi, J, 2001) |
| "Sixty-one percent of migraineurs and 73% of cluster patients noted a decrease in pain with divalproex sodium and continued that therapy for more than 3 months." | 1.31 | Divalproex sodium in the treatment of migraine and cluster headaches. ( Freitag, FG; Gallagher, RM; Mueller, LL, 2002) |
| "Valproic acid is an effective antiseizure medication that is also used for other indications such as migraine prophylaxis." | 1.30 | Multiorgan system failure caused by valproic acid toxicity. ( Pinkston, R; Walker, LA, 1997) |
| "A relationship between epilepsy and migraine has long been postulated, but the nature of this interaction is still debated." | 1.30 | Migraine with visual aura and photosensitive epileptic seizures. ( Bartolomei, F; Donnet, A, 1997) |
| "The adverse event profile of long-term divalproex therapy for epilepsy is well established, but little is known about the tolerability or safety of divalproex in long-term migraine prophylaxis." | 1.30 | Safety of divalproex sodium in migraine prophylaxis: an open-label, long-term study. Long-term Safety of Depakote in Headache Prophylaxis Study Group. ( Collins, SD; Silberstein, SD, 1999) |
| "Clinicians who treat migraineurs with divalproex sodium do not need to be overly preoccupied with monitoring of drug levels and liver function tests." | 1.29 | Divalproex sodium: migraine treatment and monitoring. ( Silberstein, SD; Wilmore, LJ, 1996) |
| "Valproic acid has been shown to be effective in migraine prophylaxis." | 1.29 | High-dose versus low-dose valproic acid as a prophylactic medication. ( Goldstein, J; Taylor, K, 1996) |
| "22 patients with severe migraine resistant to previous prophylactic treatments participated in a prospective open trial of valproate in migraine prophylaxis; 17 had common and 5 classic migraine." | 1.27 | Valproate: a new drug in migraine prophylaxis. ( Sørensen, KV, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.45) | 18.7374 |
| 1990's | 41 (18.39) | 18.2507 |
| 2000's | 77 (34.53) | 29.6817 |
| 2010's | 75 (33.63) | 24.3611 |
| 2020's | 29 (13.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gaudio, M | 1 |
| Konstantara, E | 1 |
| Joy, M | 1 |
| van Vlymen, J | 1 |
| de Lusignan, S | 1 |
| Nurathirah, MN | 1 |
| Yazid, MB | 1 |
| Norhayati, MN | 1 |
| Baharuddin, KA | 1 |
| Abu Bakar, MA | 1 |
| Dogruyol, S | 1 |
| Gur, STA | 1 |
| Akbas, I | 1 |
| Kocak, MB | 1 |
| Kocak, AO | 1 |
| Ceylan, M | 1 |
| Tekyol, D | 1 |
| Ferrari, MD | 3 |
| Zuurbier, KWM | 1 |
| Barash, S | 1 |
| Ning, X | 1 |
| Cohen, JM | 1 |
| Dolgorukova, A | 1 |
| Potapenko, AV | 1 |
| Murzina, AA | 1 |
| Lyubashina, OA | 1 |
| Y Sokolov, A | 1 |
| Evers, S | 2 |
| Frese, A | 1 |
| Summ, O | 1 |
| Husstedt, IW | 1 |
| Marziniak, M | 1 |
| Suda, C | 1 |
| Kondo, Y | 1 |
| Kanaoka, K | 1 |
| Watanabe, J | 1 |
| Shafie'ei, M | 1 |
| Kouhanjani, MF | 1 |
| Akbari, Z | 1 |
| Sarvipour, N | 1 |
| Shekouh, D | 1 |
| Gholampour, M | 1 |
| Ardestani, PM | 1 |
| Nemati, H | 1 |
| Puliappadamb, HM | 3 |
| Maiti, R | 3 |
| Mishra, A | 3 |
| Jena, M | 3 |
| Mishra, BR | 3 |
| Chang, WJ | 1 |
| Ho, MP | 1 |
| Vila-Pueyo, M | 1 |
| Cuenca-León, E | 1 |
| Queirós, AC | 1 |
| Kulis, M | 1 |
| Sintas, C | 1 |
| Cormand, B | 1 |
| Martín-Subero, JI | 1 |
| Pozo-Rosich, P | 1 |
| Fernàndez-Castillo, N | 1 |
| Macaya, A | 1 |
| Lampl, C | 1 |
| MaassenVanDenBrink, A | 1 |
| Deligianni, CI | 1 |
| Gil-Gouveia, R | 1 |
| Jassal, T | 1 |
| Sanchez-Del-Rio, M | 1 |
| Reuter, U | 2 |
| Uluduz, D | 1 |
| Versijpt, J | 1 |
| Zeraatkar, D | 1 |
| Sacco, S | 1 |
| Abdelmonem, H | 1 |
| Abdelhay, HM | 1 |
| Abdelwadoud, GT | 1 |
| Alhosini, ANM | 1 |
| Ahmed, AE | 1 |
| Mohamed, SW | 1 |
| Al-Dardery, NM | 1 |
| Abd-ElGawad, M | 1 |
| Kamel, MA | 1 |
| Ingram, EE | 1 |
| Bocklud, BE | 1 |
| Corley, SC | 1 |
| Granier, MA | 1 |
| Neuchat, EE | 1 |
| Ahmadzadeh, S | 1 |
| Shekoohi, S | 1 |
| Kaye, AD | 1 |
| Chen, JJ | 1 |
| Zeng, BS | 1 |
| Su, KP | 1 |
| Wu, YC | 1 |
| Tu, YK | 1 |
| Stubbs, B | 1 |
| Chen, TY | 1 |
| Zeng, BY | 1 |
| Chen, YW | 1 |
| Hsu, CW | 1 |
| Tseng, PT | 1 |
| Diener, HC | 3 |
| Rizzoli, P | 1 |
| Amanat, M | 2 |
| Togha, M | 3 |
| Agah, E | 1 |
| Ramezani, M | 1 |
| Tavasoli, AR | 1 |
| Azizi Malamiri, R | 1 |
| Fashandaky, F | 1 |
| Heidari, M | 2 |
| Salehi, M | 1 |
| Eshaghi, H | 1 |
| Ashrafi, MR | 3 |
| Tsaousi, G | 1 |
| Pourzitaki, C | 1 |
| Siafis, S | 1 |
| Kyrgidis, A | 1 |
| Grosomanidis, V | 1 |
| Kouvelas, D | 1 |
| Papazisis, G | 1 |
| Skora, CE | 1 |
| Worden, LT | 1 |
| Oakley, CB | 2 |
| Kouremenos, E | 1 |
| Arvaniti, C | 1 |
| Constantinidis, TS | 1 |
| Giannouli, E | 1 |
| Fakas, N | 1 |
| Kalamatas, T | 1 |
| Kararizou, E | 1 |
| Naoumis, D | 1 |
| Mitsikostas, DD | 2 |
| Kano, Y | 1 |
| Oguri, T | 1 |
| Sugiyama, H | 1 |
| Kikui, S | 1 |
| Takeshima, T | 1 |
| Yuasa, H | 1 |
| Riggins, N | 1 |
| Ehrlich, A | 1 |
| Sawhney, H | 1 |
| Dapkus, L | 1 |
| Levin, M | 1 |
| Gaki, E | 1 |
| Siapkara, A | 1 |
| Morgan, S | 1 |
| Branch, S | 1 |
| Cui, XY | 1 |
| Sun, SM | 1 |
| Liu, J | 1 |
| Wu, QY | 1 |
| Zhang, JF | 1 |
| Li, X | 1 |
| Werner, K | 1 |
| Qaiser, S | 1 |
| Kabbouche, M | 1 |
| Murphy, B | 1 |
| Maconochie, I | 1 |
| Hershey, AD | 1 |
| Wang, F | 1 |
| Zhang, H | 1 |
| Wang, L | 1 |
| Cao, Y | 1 |
| He, Q | 1 |
| Khani, S | 1 |
| Hejazi, SA | 1 |
| Yaghoubi, M | 1 |
| Sharifipour, E | 1 |
| Viau, JA | 1 |
| Patel, D | 1 |
| Cheng, W | 1 |
| Cortel-LeBlanc, M | 1 |
| Nath, A | 1 |
| Perry, JJ | 1 |
| Kashipazha, D | 1 |
| Ghadikolaei, HS | 1 |
| Siavashi, M | 1 |
| Holder, SD | 1 |
| Prakash, S | 2 |
| Adroja, B | 1 |
| Parekh, H | 1 |
| Ebrahimi-Monfared, M | 1 |
| Sharafkhah, M | 1 |
| Abdolrazaghnejad, A | 1 |
| Mohammadbeigi, A | 1 |
| Faraji, F | 1 |
| Yi, L | 2 |
| Wu, Q | 1 |
| Chen, N | 2 |
| Song, G | 2 |
| Wang, C | 1 |
| Zou, Q | 1 |
| Zhang, Z | 3 |
| Karlsson Lind, L | 1 |
| Wide, K | 1 |
| Wettermark, B | 1 |
| von Euler, M | 1 |
| Zafar, MS | 2 |
| Stewart, AM | 2 |
| Toupin, DN | 1 |
| Cook, AM | 3 |
| Baumann, RJ | 3 |
| Patterson-Gentile, C | 1 |
| Szperka, CL | 1 |
| Wentzell, N | 1 |
| Haug, U | 1 |
| Schink, T | 1 |
| Engel, S | 1 |
| Liebentraut, J | 1 |
| Linder, R | 1 |
| Onken, M | 1 |
| Schaefer, C | 1 |
| Dathe, K | 1 |
| Vatzaki, E | 1 |
| Straus, S | 1 |
| Dogne, JM | 1 |
| Garcia Burgos, J | 1 |
| Girard, T | 1 |
| Martelletti, P | 1 |
| Karimi, N | 1 |
| Razian, A | 1 |
| Jackson, JL | 1 |
| Kuriyama, A | 1 |
| Kuwatsuka, Y | 1 |
| Nickoloff, S | 1 |
| Storch, D | 1 |
| Jackson, W | 1 |
| Zhang, ZJ | 1 |
| Hayashino, Y | 1 |
| Kim, H | 1 |
| Faught, E | 1 |
| Thurman, DJ | 1 |
| Fishman, J | 1 |
| Kalilani, L | 1 |
| van Dongen, RM | 1 |
| Waaijer, LC | 1 |
| Onderwater, GLJ | 1 |
| Terwindt, GM | 1 |
| Krymchantowski, AV | 3 |
| Krymchantowski, AG | 1 |
| Jevoux, C | 1 |
| Kalita, J | 2 |
| Bhoi, SK | 2 |
| Misra, UK | 2 |
| Linde, M | 1 |
| Mulleners, WM | 3 |
| Chronicle, EP | 3 |
| McCrory, DC | 1 |
| Hoffmann, J | 1 |
| Akerman, S | 1 |
| Goadsby, PJ | 4 |
| Kossoff, EH | 1 |
| Friedman, BW | 3 |
| Garber, L | 3 |
| Yoon, A | 1 |
| Solorzano, C | 1 |
| Wollowitz, A | 1 |
| Esses, D | 1 |
| Bijur, PE | 1 |
| Gallagher, EJ | 3 |
| Gentile, S | 1 |
| Sarchielli, P | 4 |
| Messina, P | 1 |
| Cupini, LM | 4 |
| Tedeschi, G | 1 |
| Di Piero, V | 1 |
| Livrea, P | 1 |
| Pini, LA | 1 |
| Bernardi, G | 1 |
| Bono, G | 1 |
| Sandrini, G | 1 |
| Caproni, S | 3 |
| Corbelli, I | 3 |
| Pisani, F | 2 |
| Beghi, E | 1 |
| Calabresi, P | 4 |
| Factor, SA | 1 |
| Jankovic, J | 1 |
| Mazaheri, S | 1 |
| Poorolajal, J | 1 |
| Hosseinzadeh, A | 1 |
| Fazlian, MM | 1 |
| Sheridan, D | 1 |
| Sun, B | 1 |
| O'Brien, P | 1 |
| Hansen, M | 1 |
| Pisanu, C | 1 |
| Congiu, D | 1 |
| Squassina, A | 1 |
| Patrinos, GP | 1 |
| Del Zompo, M | 1 |
| Kaufmann, D | 1 |
| Bates, EA | 1 |
| Yagen, B | 2 |
| Bialer, M | 2 |
| Saunders, GH | 1 |
| Wilcox, K | 1 |
| White, HS | 1 |
| Brennan, KC | 2 |
| Ghaderibarmi, F | 1 |
| Tavakkoli, N | 1 |
| Pourshoghi, A | 1 |
| Danesh, A | 1 |
| Tabby, DS | 1 |
| Grothusen, J | 1 |
| Pourrezaei, K | 1 |
| Tipton, AF | 1 |
| Tarash, I | 1 |
| McGuire, B | 1 |
| Charles, A | 1 |
| Pradhan, AA | 1 |
| Mathias, S | 1 |
| Albuja, AC | 1 |
| Bensalem-Owen, M | 1 |
| Kapoor, S | 1 |
| Vreeburg, SA | 1 |
| Leijten, FS | 1 |
| Sommer, IE | 1 |
| Balon, R | 1 |
| Riba, M | 1 |
| Li, Y | 1 |
| Zhang, Q | 1 |
| Qi, D | 1 |
| Zhang, L | 2 |
| Li, Q | 1 |
| Brugger, F | 1 |
| Bhatia, KP | 1 |
| Besag, FM | 1 |
| Atasayar, G | 1 |
| Eryilmaz, IE | 1 |
| Karli, N | 1 |
| Egeli, U | 1 |
| Zarifoglu, M | 1 |
| Cecener, G | 1 |
| Taskapilioglu, O | 1 |
| Tunca, B | 1 |
| Yildirim, O | 1 |
| Ak, S | 1 |
| Tezcan, G | 1 |
| Can, FE | 1 |
| Chirchiglia, D | 1 |
| Torre, AD | 1 |
| Volpentesta, G | 1 |
| Lavano, SM | 1 |
| Lavano, A | 1 |
| Borzi', G | 1 |
| Li, R | 1 |
| Liu, Y | 1 |
| Zhang, Y | 1 |
| Turner, DP | 1 |
| Golding, AN | 1 |
| Houle, TT | 1 |
| Aluisio, AR | 1 |
| Zehtabchi, S | 1 |
| Romoli, M | 1 |
| Costa, C | 1 |
| Siliquini, S | 1 |
| Eusebi, P | 1 |
| Bedetti, C | 1 |
| He, A | 1 |
| Song, D | 1 |
| Li, C | 1 |
| Joffe, H | 1 |
| Hayes, FJ | 1 |
| Apostol, G | 3 |
| Cady, RK | 1 |
| Laforet, GA | 3 |
| Robieson, WZ | 3 |
| Olson, E | 2 |
| Abi-Saab, WM | 3 |
| Saltarelli, M | 2 |
| Hikita, T | 1 |
| Kodama, H | 1 |
| Nakamoto, N | 1 |
| Kaga, F | 1 |
| Amakata, K | 1 |
| Ogita, K | 1 |
| Kaneko, S | 1 |
| Fujii, Y | 1 |
| Yanagawa, Y | 1 |
| Rapoport, AM | 4 |
| Pakalnis, A | 2 |
| Lewis, DW | 1 |
| Fugate, JM | 1 |
| Saltarelli, MD | 1 |
| Unalp, A | 1 |
| Uran, N | 1 |
| Oztürk, A | 1 |
| Bakola, E | 1 |
| Skapinakis, P | 1 |
| Tzoufi, M | 1 |
| Damigos, D | 1 |
| Mavreas, V | 1 |
| Yaldo, AZ | 1 |
| Wertz, DA | 1 |
| Rupnow, MF | 1 |
| Quimbo, RM | 1 |
| Cuvellier, JC | 1 |
| Lippi, G | 1 |
| Targher, G | 1 |
| Franchini, M | 1 |
| Shah, ND | 1 |
| Terbach, N | 1 |
| Williams, RS | 1 |
| Andreou, AP | 1 |
| Shields, KG | 1 |
| Hamada, J | 1 |
| Keyvan, G | 1 |
| Abolfazl, MB | 1 |
| Wright, W | 1 |
| Vikelis, M | 1 |
| Hamed, SA | 1 |
| Avraham, SB | 1 |
| Har-Gil, M | 1 |
| Watemberg, N | 1 |
| Lovell, BV | 1 |
| Marmura, MJ | 1 |
| D'Amico, D | 3 |
| Verrotti, A | 1 |
| Coppola, G | 1 |
| D'Egidio, C | 1 |
| Parisi, P | 1 |
| Chiarelli, F | 1 |
| Shahien, R | 1 |
| Saleh, SA | 1 |
| Bowirrat, A | 1 |
| Bidabadi, E | 1 |
| Mashouf, M | 1 |
| Aydin, M | 1 |
| Kabakus, N | 1 |
| Bozdag, S | 1 |
| Ertugrul, S | 1 |
| Bogdanov, VB | 2 |
| Multon, S | 2 |
| Chauvel, V | 2 |
| Bogdanova, OV | 2 |
| Prodanov, D | 1 |
| Makarchuk, MY | 2 |
| Schoenen, J | 3 |
| Hoffmann, U | 1 |
| Dileköz, E | 1 |
| Kudo, C | 1 |
| Ayata, C | 1 |
| Jevoux, CC | 1 |
| Kanner, AM | 1 |
| Afshari, D | 1 |
| Rafizadeh, S | 1 |
| Rezaei, M | 2 |
| Martikainen, MH | 1 |
| Roine, S | 1 |
| Jevoux, Cda C | 1 |
| Straube, A | 1 |
| Gaul, C | 1 |
| Burakgazi, E | 1 |
| Akbar, U | 1 |
| Kelly, J | 1 |
| Chakor, RT | 1 |
| Bharote, HS | 1 |
| Gelfand, AA | 1 |
| Artto, V | 1 |
| Kallela, M | 1 |
| Koulchitsky, SV | 1 |
| Renshaw, PF | 1 |
| Shah, L | 1 |
| Rana, S | 1 |
| Valeriano, J | 1 |
| Scott, TF | 1 |
| Bostani, A | 1 |
| Rajabi, A | 1 |
| Moradian, N | 1 |
| Razazian, N | 1 |
| Labiner, DM | 1 |
| Schwartz, TH | 1 |
| Karpitskiy, VV | 1 |
| Sohn, RS | 1 |
| Serdaroglu, G | 1 |
| Erhan, E | 1 |
| Tekgul, H | 1 |
| Oksel, F | 1 |
| Erermis, S | 1 |
| Uyar, M | 1 |
| Tutuncuoglu, S | 1 |
| Corbo, J | 1 |
| Fusco, C | 1 |
| Capone, C | 1 |
| Faienza, C | 1 |
| Silberstein, SD | 5 |
| Winner, PK | 2 |
| Chmiel, JJ | 1 |
| Isoherranen, N | 1 |
| Tanen, DA | 1 |
| Miller, S | 1 |
| French, T | 1 |
| Riffenburgh, RH | 1 |
| Fragoso, YD | 1 |
| Freitag, FG | 5 |
| Spry, H | 1 |
| McDiarmid, T | 1 |
| Mayer, J | 1 |
| Stanton, RN | 1 |
| Filatova, EG | 1 |
| Klimov, MV | 1 |
| Stillman, MJ | 1 |
| Zajac, D | 1 |
| Rybicki, LA | 1 |
| Pascual, J | 3 |
| Leira, R | 2 |
| Láinez, JM | 1 |
| Fasmer, OB | 1 |
| Oedegaard, KJ | 1 |
| Leniger, T | 2 |
| Pageler, L | 1 |
| Stude, P | 1 |
| Limmroth, V | 4 |
| Mannix, LK | 1 |
| ten Berg, K | 1 |
| van Oppen, AC | 1 |
| Nikkels, PG | 1 |
| Gittenberger-de Groot, AC | 1 |
| van der Voet, GB | 1 |
| Brilstra, EH | 1 |
| Lindhout, D | 1 |
| Steinberg, J | 1 |
| Evans, RW | 1 |
| Láinez, MJ | 1 |
| Green, MW | 1 |
| Giordano, S | 1 |
| Jiang, P | 1 |
| Jafari, M | 1 |
| Smith, TB | 1 |
| Joubert, J | 1 |
| Shabanian, R | 1 |
| Zamani, GR | 1 |
| Mahfelati, F | 1 |
| Shaygannejad, V | 1 |
| Janghorbani, M | 1 |
| Ghorbani, A | 1 |
| Ashtary, F | 1 |
| Zakizade, N | 1 |
| Nasr, V | 1 |
| Schrader, H | 1 |
| Stovner, J | 1 |
| Tronvik, E | 1 |
| Waberzinek, G | 1 |
| Marková, J | 1 |
| Mastík, J | 1 |
| Galletti, F | 1 |
| Rossi, C | 1 |
| Taylor, LM | 1 |
| Farzam, F | 1 |
| Lewis, DA | 1 |
| Kuhn, RJ | 1 |
| Rosenberg, G | 1 |
| Puppe, A | 1 |
| Millán-Guerrero, RO | 1 |
| Isais-Millán, R | 1 |
| Barreto-Vizcaíno, S | 1 |
| Rivera-Castaño, L | 1 |
| Garcia-Solorzano, A | 1 |
| López-Blanca, C | 1 |
| Membrila-Maldonado, M | 1 |
| Muñoz-Solis, R | 1 |
| Arnold, G | 3 |
| Schuh-Hofer, S | 1 |
| Blumenfeld, AM | 1 |
| Schim, JD | 1 |
| Chippendale, TJ | 1 |
| Mansoureh, T | 1 |
| Rahmat Jirde, M | 1 |
| Nilavari, K | 1 |
| Ashrafian, H | 1 |
| Razeghi, S | 1 |
| Kohan, L | 1 |
| Frazee, LA | 1 |
| Foraker, KC | 1 |
| Nakazato, Y | 1 |
| Tamura, N | 1 |
| Shimazu, K | 1 |
| Mathew, NT | 5 |
| Saper, JR | 1 |
| Rankin, L | 1 |
| Markley, HG | 1 |
| Solomon, S | 1 |
| Silber, CJ | 1 |
| Deaton, RL | 1 |
| Kaube, H | 1 |
| Rothrock, JF | 4 |
| Kelly, NM | 1 |
| Brody, ML | 1 |
| Golbeck, A | 1 |
| Hering, R | 4 |
| Steiner, TJ | 1 |
| Jensen, R | 1 |
| Brinck, T | 1 |
| Olesen, J | 1 |
| Solomon, GD | 1 |
| Welch, KM | 1 |
| Raskin, NH | 2 |
| Gordon, CR | 1 |
| Kuritzky, A | 3 |
| Doweck, I | 1 |
| Spitzer, O | 1 |
| Shupak, A | 1 |
| Wilmore, LJ | 1 |
| Lenaerts, M | 1 |
| Bastings, E | 1 |
| Sianard, J | 1 |
| Taylor, K | 1 |
| Goldstein, J | 2 |
| Cutrer, FM | 1 |
| Moskowitz, MA | 1 |
| Klapper, J | 1 |
| Pinkston, R | 1 |
| Walker, LA | 1 |
| Swain, RA | 1 |
| Kaplan, B | 1 |
| Kaniecki, RG | 1 |
| Zurlinden, J | 2 |
| Moreno, MS | 1 |
| Díez-Tejedor, E | 1 |
| Suzuki, N | 1 |
| Higelin, F | 1 |
| Annoni, JM | 1 |
| Donnet, A | 1 |
| Bartolomei, F | 1 |
| Ghose, K | 1 |
| Niven, B | 1 |
| Einhäupl, KM | 2 |
| García-Herrero, D | 1 |
| Fernández-Torre, JL | 1 |
| Barrasa, J | 1 |
| Calleja, J | 1 |
| Landy, SH | 1 |
| McGinnis, J | 1 |
| Putnam, GP | 1 |
| O'Quinn, S | 1 |
| Bolden-Watson, CP | 1 |
| Davis, RL | 1 |
| Gutterman, DL | 1 |
| Fox, AW | 1 |
| Mendizabal, JE | 2 |
| Delva, NJ | 1 |
| Horgan, SA | 1 |
| Hawken, ER | 1 |
| Friedenberg, S | 1 |
| Dodick, DW | 1 |
| Caruso, JM | 1 |
| Brown, WD | 1 |
| Exil, G | 1 |
| Gascon, GG | 1 |
| Wiemann, M | 1 |
| Bingmann, D | 1 |
| Hufnagel, A | 1 |
| Bonnet, U | 1 |
| Palmer, JE | 1 |
| Rolan, P | 1 |
| Kailasam, J | 1 |
| Meadors, L | 1 |
| Chernyschev, O | 1 |
| Gentry, P | 1 |
| Norton, J | 1 |
| Ophoff, RA | 1 |
| van den Maagdenberg, AM | 1 |
| Roon, KI | 1 |
| Frants, RR | 1 |
| Diamond, S | 1 |
| Diamond, ML | 1 |
| Urban, GJ | 1 |
| Collins, SD | 2 |
| Zakrzewska, JM | 1 |
| Cohen, GL | 1 |
| Kinze, S | 1 |
| Clauss, M | 1 |
| Wolf, T | 1 |
| Dreier, JP | 1 |
| Greenberg, G | 1 |
| Drake, ME | 1 |
| Paolichi, J | 1 |
| Vredeveld, JW | 1 |
| Koehler, PJ | 1 |
| Pothmann, R | 1 |
| Uberall, M | 1 |
| Naumann, E | 1 |
| Gerber, WD | 1 |
| Henry, P | 1 |
| Gallagher, RM | 1 |
| Mueller, LL | 1 |
| Carlson, HA | 1 |
| Saper, J | 1 |
| Silberstein, S | 1 |
| Mathew, N | 1 |
| Deaton, R | 1 |
| Sommerville, K | 1 |
| Gilad, I | 1 |
| Laron, Z | 1 |
| Sørensen, KV | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Intranasal Lidocaine to Treat Pediatric Migraine in the Emergency Department[NCT03576820] | Phase 3 | 50 participants (Anticipated) | Interventional | 2018-10-15 | Recruiting | ||
| Efficacy of Memantine Compared With Sodium Valproate in the Prophylactic Treatment of Episodic Migraine.[NCT04698525] | Phase 3 | 33 participants (Actual) | Interventional | 2019-02-15 | Completed | ||
| Targeted Alterations in n-3 and n-6 Fatty Acids for the Management of Mood Variability in the Maintenance Phase of Bipolar Disorder[NCT02272010] | 83 participants (Actual) | Interventional | 2014-10-31 | Completed | |||
| IM Ketorolac vs Diclofenac Potassium Powder for Oral Solution (Cambia) for the Acute Treatment of Severe Migraine[NCT02664116] | Phase 4 | 40 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| The Check Trial: A Comparison of Headache Treatment in the ED: Compazine Versus Ketamine. A Multi-Center, Randomized Double-Blind, Clinical Control Trial.[NCT02657031] | Phase 4 | 54 participants (Actual) | Interventional | 2016-03-17 | Completed | ||
| Intravenous Fluids in Benign Headaches Trail: A Randomized Single Blind Clinical Trial[NCT03185130] | Phase 4 | 58 participants (Actual) | Interventional | 2017-05-16 | Completed | ||
| Phase II Study to Assess the Efficacy and Safety of Subcutaneous AGX-201 for Migraine Prophylaxis[NCT02021474] | Phase 2 | 130 participants (Anticipated) | Interventional | 2022-10-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To compare the average weight in both arms before and after Valproate and Memantine administration. The weight will be measured in kilograms, and the initial against the final will be compared. (NCT04698525)
Timeframe: Three months
| Intervention | kilograms (Mean) | |
|---|---|---|
| Pre-treatment | Post-treatment | |
| Memantine | 64.44 | 64.19 |
| Valproate Group | 71.77 | 72.13 |
In a double-blind clinical trial, we compared two active drugs (mamantine vs. valproate) three months after initiation, looking for changes in the average number of days of migraine attack presentation per month and comparing the three months before with the three months after treatment administration with two active drugs. (NCT04698525)
Timeframe: Three months before treatment (Pretreatment), three months after initiating treatment (post-treatment)
| Intervention | Migraine days by month. (Mean) | |
|---|---|---|
| Pretreatment | Post-treatment | |
| Memantine | 5.31 | 0.93 |
| Valproate Group | 5.35 | 0.77 |
"The possible reduction in the average on the visual analog scale (0-10) comparing three months before and after three months of the treatment with both drugs. We measured both arms of the study.~0 means without pain. 10 means the worst possible pain in the concept of the patient." (NCT04698525)
Timeframe: Three months previous and three months after the treatment.
| Intervention | Score on a scale (Mean) | |
|---|---|---|
| Pre-treatment | Post-treatment | |
| Memantine | 8.5 | 4.28 |
| Valproate Group | 8.94 | 2.5 |
"To compare the average of Memantine against the group that receives Valproate before and after starting preventive treatment. Using the Migraine Disability Assessment scale (The score is the sum of days missed from work or school, days of housework missed, days of missed non-work activities, and days of work or school plus days of housework in which productivity in the last three months) to compare punctuation changes. The MIDAS score is divided into four degrees, the minimum score is 0 points, and the maximum score is 70. A higher value represents a higher difficulty to carry out a satisfactory lifestyle, and a score higher than 20 points already represents a high limitation to enjoying daily activities:~Grade I (0-5 points): Slight limitations and few patient treatment needs. Grade II (6-10 points): Moderate limitations and treatment needs. Grade III (11-20 points) and IV (21 or more points): Severe and significant punctuation treatment needs." (NCT04698525)
Timeframe: Three months.
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Pre-treatment | Post-treatment | |
| Memantine | 60.87 | 15.57 |
| Valproate Group | 51.92 | 10.53 |
Reduction in 100 mm Visual Analog Scale (VAS) Score. The maximum possible change in VAS score is 100 mm, representing the complete relief of maximum anxiety. A change of 0 mm corresponds to no change in anxiety level, and a negative value indicates worsening of the anxiety after the medication. (NCT02657031)
Timeframe: 0-60 minutes
| Intervention | mm (Mean) |
|---|---|
| Control Arm | 33.7 |
| Study Arm | 21.2 |
Reduction in 100 mm Visual Analog Scale (VAS) Score. Positive values represent a reduction in headache severity. The maximum possible change in VAS score is 100 mm, representing the complete relief of a maximally severe headache. A change of 0 mm corresponds to no change in headache severity, and a negative value indicates worsening of the headache after the medication. (NCT02657031)
Timeframe: 0-60 minutes
| Intervention | mm (Mean) |
|---|---|
| Control Arm | 63.5 |
| Study Arm | 43.5 |
Reduction in 100 mm Visual Analog Scale (VAS) Score. The maximum possible change in VAS score is 100 mm, representing the complete relief of maximum nausea. A change of 0 mm corresponds to no change in nausea level, and a negative value indicates worsening of the nausea after the medication. (NCT02657031)
Timeframe: 0-60 minutes
| Intervention | mm (Mean) |
|---|---|
| Control Arm | 38.9 |
| Study Arm | 22.9 |
Yes/No (NCT02657031)
Timeframe: 0-60 minutes
| Intervention | participants (Number) |
|---|---|
| Control Arm | 2 |
| Study Arm | 3 |
Yes/No (NCT02657031)
Timeframe: 0-60 minutes
| Intervention | participants (Number) |
|---|---|
| Control Arm | 3 |
| Study Arm | 3 |
72 reviews available for valproic acid and Migraine Disorders
| Article | Year |
|---|---|
Efficacy of ketorolac in the treatment of acute migraine attack: A systematic review and meta-analysis.
Topics: Caffeine; Dexamethasone; Diclofenac; Humans; Ketorolac; Metoclopramide; Migraine Disorders; Pain; Ph | 2022 |
Application of cinnarizine in migraine prevention: A systematic review and meta-analysis.
Topics: Activities of Daily Living; Cinnarizine; Humans; Migraine Disorders; Propranolol; Quality of Life; V | 2022 |
Efficacy and Safety of Melatonin as Prophylaxis for Migraine in Adults: A Meta-analysis.
Topics: Adult; Amitriptyline; Analgesics; Humans; Melatonin; Migraine Disorders; Valproic Acid | 2022 |
Efficacy and Safety of Melatonin as Prophylaxis for Migraine in Adults: A Meta-analysis.
Topics: Adult; Amitriptyline; Analgesics; Humans; Melatonin; Migraine Disorders; Valproic Acid | 2022 |
Efficacy and Safety of Melatonin as Prophylaxis for Migraine in Adults: A Meta-analysis.
Topics: Adult; Amitriptyline; Analgesics; Humans; Melatonin; Migraine Disorders; Valproic Acid | 2022 |
Efficacy and Safety of Melatonin as Prophylaxis for Migraine in Adults: A Meta-analysis.
Topics: Adult; Amitriptyline; Analgesics; Humans; Melatonin; Migraine Disorders; Valproic Acid | 2022 |
The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis.
Topics: Adult; Amitriptyline; Antibodies, Monoclonal; Calcitonin Gene-Related Peptide; Gabapentin; Humans; M | 2023 |
The efficacy and safety of metoclopramide in relieving acute migraine attacks compared with other anti-migraine drugs: a systematic review and network meta-analysis of randomized controlled trials.
Topics: Chlorpromazine; Granisetron; Headache; Humans; Ketorolac; Metoclopramide; Migraine Disorders; Nausea | 2023 |
Non-CGRP Antagonist/Non-Triptan Options for Migraine Disease Treatment: Clinical Considerations.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Calcium Channel Blockers; Drug-Relat | 2023 |
Network Meta-analysis of Different Treatments for Vestibular Migraine.
Topics: Adult; Female; Humans; Male; Migraine Disorders; Network Meta-Analysis; Propranolol; Valproic Acid; | 2023 |
Chronic migraine and medication overuse.
Topics: Headache; Humans; Migraine Disorders; Prescription Drug Overuse; Valproic Acid | 2023 |
Levetiracetam as preventive treatment in adults with migraine: an up-to-date systematic review and quantitative meta-analysis.
Topics: Adult; Anticonvulsants; Humans; Levetiracetam; Migraine Disorders; Randomized Controlled Trials as T | 2020 |
The efficacy and safety of valproate medications for migraine in adults: a meta-analysis.
Topics: Adult; Anticonvulsants; Humans; Migraine Disorders; Valproic Acid | 2020 |
Intravenous Migraine Treatment in Children and Adolescents.
Topics: Administration, Intravenous; Adolescent; Akathisia, Drug-Induced; Anesthetics, Local; Anti-Inflammat | 2020 |
Intravenous sodium valproate for acute migraine in the emergency department: A meta-analysis.
Topics: Administration, Intravenous; Adult; Emergency Service, Hospital; Female; Humans; Migraine Disorders; | 2020 |
Sodium Valproate Versus Dopamine Antagonists for Acute Migraine in the Emergency Department: A Systematic Review.
Topics: Adult; Dopamine Antagonists; Emergency Service, Hospital; Humans; Migraine Disorders; Pain; Valproic | 2022 |
Psychotic and Bipolar Disorders: Bipolar Disorder.
Topics: Antimanic Agents; Bipolar Disorder; Cardiovascular Diseases; Chronic Pain; Comorbidity; Family Pract | 2017 |
The Changing Landscape of Pediatric Migraine Therapy: A Review.
Topics: Adolescent; Adrenergic beta-Antagonists; Amitriptyline; Analgesics, Non-Narcotic; Anti-Inflammatory | 2018 |
Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis.
Topics: Adrenergic beta-Antagonists; Adult; Clinical Trials as Topic; Female; Humans; Male; Migraine Disorde | 2019 |
Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults.
Topics: Adult; Anticonvulsants; Flunarizine; Fructose; Humans; Migraine Disorders; Propranolol; Randomized C | 2013 |
Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults.
Topics: Adult; Anticonvulsants; Flunarizine; Fructose; Humans; Migraine Disorders; Propranolol; Randomized C | 2013 |
Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults.
Topics: Adult; Anticonvulsants; Flunarizine; Fructose; Humans; Migraine Disorders; Propranolol; Randomized C | 2013 |
Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults.
Topics: Adult; Anticonvulsants; Flunarizine; Fructose; Humans; Migraine Disorders; Propranolol; Randomized C | 2013 |
Efficacy and mechanism of anticonvulsant drugs in migraine.
Topics: Animals; Anticonvulsants; Cortical Spreading Depression; Fructose; Humans; Migraine Disorders; Rando | 2014 |
Migraine and epilepsy in the pediatric population.
Topics: Anticonvulsants; Child; Child, Preschool; Comorbidity; Diagnosis, Differential; Diet, Ketogenic; Epi | 2014 |
Risks of neurobehavioral teratogenicity associated with prenatal exposure to valproate monotherapy: a systematic review with regulatory repercussions.
Topics: Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Bipolar Di | 2014 |
Prevention of migraine attacks. First-choice treatments.
Topics: Adrenergic beta-Antagonists; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tric | 2015 |
Valproate-Associated Parkinsonism: A Critical Review of the Literature.
Topics: Anticonvulsants; Dopamine; Dopamine Plasma Membrane Transport Proteins; Humans; Migraine Disorders; | 2016 |
Unveiling the relative efficacy, safety and tolerability of prophylactic medications for migraine: pairwise and network-meta analysis.
Topics: Adult; Amines; Amitriptyline; Anticonvulsants; Cyclohexanecarboxylic Acids; Dizziness; Female; Fruct | 2017 |
Menstrual cycle dysfunction associated with neurologic and psychiatric disorders: their treatment in adolescents.
Topics: Adolescent; Amenorrhea; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Bone and Bones; Epi | 2008 |
Medication overuse headache: awareness, detection and treatment.
Topics: Communication; Fructose; Headache Disorders, Secondary; Humans; Medication Therapy Management; Migra | 2008 |
Anticonvulsant drugs for pediatric migraine prevention: an evidence-based review.
Topics: Adolescent; Age Factors; Anticonvulsants; Child; Clinical Trials as Topic; Evidence-Based Medicine; | 2009 |
[Antiepileptic drugs for the prevention of pediatric migraine].
Topics: Adolescent; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Drug Tolerance; Fructose; G | 2009 |
Structure-function studies for the panacea, valproic acid.
Topics: Animals; Anticonvulsants; Bipolar Disorder; Epilepsy; gamma-Aminobutyric Acid; Glycogen Synthase Kin | 2009 |
[Use of antiepileptic drugs for the preventive treatment of migraine].
Topics: Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Administration Schedule; Fructose; Gabape | 2009 |
Role of antiepileptic drugs as preventive agents for migraine.
Topics: Adult; Anticonvulsants; Child; Chronic Disease; Clinical Trials as Topic; Fructose; Humans; Migraine | 2010 |
A migraine variant with abdominal colic and Alice in Wonderland syndrome: a case report and review.
Topics: Brain; Colic; Electroencephalography; Evoked Potentials; Hallucinations; Humans; Intestinal Diseases | 2010 |
Valproate semisodium ER for migraine and cluster headache prophylaxis.
Topics: Cluster Headache; Humans; Migraine Disorders; Valproic Acid | 2010 |
Are antiepileptic drugs used in the treatment of migraine associated with an increased risk of suicidality?
Topics: Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Labeling; Fructose; Gabapentin; gamma-Ami | 2011 |
Rapid improvement of a complex migrainous episode with sodium valproate in a patient with CADASIL.
Topics: Adult; CADASIL; GABA Agents; Humans; Male; Migraine Disorders; Valproic Acid | 2012 |
Controversies in migraine: monotherapy.
Topics: Analgesics; Antidepressive Agents; Drug Therapy, Combination; Humans; Migraine Disorders; Valproic A | 2012 |
Treatment of pediatric migraine in the emergency room.
Topics: Adolescent; Age Distribution; Age of Onset; Analgesics; Antiemetics; Child; Child, Preschool; Dihydr | 2012 |
[Treatment of prolonged migraine attack (status migrenosus)].
Topics: Anti-Inflammatory Agents; Dopamine Antagonists; Enzyme Inhibitors; Humans; Migraine Disorders; Progn | 2012 |
DP-VPA D-Pharm.
Topics: Animals; Bipolar Disorder; Clinical Trials, Phase II as Topic; Drug Evaluation, Preclinical; Epileps | 2002 |
The role of anticonvulsants in preventive migraine therapy.
Topics: Acetates; Amines; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Drug Appro | 2003 |
New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet?
Topics: Amides; Anticonvulsants; Bipolar Disorder; Epilepsy; Humans; Migraine Disorders; Valproic Acid | 2003 |
Divalproex sodium extended-release for the prophylaxis of migraine headache.
Topics: Clinical Trials as Topic; Delayed-Action Preparations; Drug Administration Schedule; GABA Agents; Hu | 2003 |
Clinical inquiries. What medication best prevents migraine in children?
Topics: Amitriptyline; Child; Evidence-Based Medicine; Humans; Migraine Disorders; Propranolol; Valproic Aci | 2003 |
[Anticonvulsants in preventive therapy of migraine].
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Fructose; Gabapentin; gamma-Aminobut | 2003 |
Divalproex in the treatment of migraine.
Topics: Animals; Anticonvulsants; Humans; Migraine Disorders; Valproic Acid | 2003 |
[Migraine and psychiatric disorders].
Topics: Antidepressive Agents; Antimanic Agents; Anxiety Disorders; Comorbidity; Humans; Mental Disorders; M | 2004 |
Clinical advances in the preventive treatment of migraine.
Topics: Amitriptyline; Fructose; Humans; Migraine Disorders; Propranolol; Topiramate; Valproic Acid | 2004 |
Anticonvulsant medications for migraine prevention.
Topics: Adult; Anticonvulsants; Female; Humans; Migraine Disorders; Treatment Outcome; Valproic Acid | 2005 |
[Migraine therapy].
Topics: Adrenergic beta-Antagonists; Fructose; Germany; Humans; Migraine Disorders; Practice Guidelines as T | 2005 |
Migraine--diagnosis and treatment.
Topics: Analgesics; Behavior Therapy; Diet Therapy; Dopamine Antagonists; Droperidol; Family Practice; Human | 2005 |
Antiepileptic drugs in migraine: from clinical aspects to cellular mechanisms.
Topics: Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Fructose; Gabapentin; gamma | 2007 |
Antiepileptic drugs in the prophylaxis of migraine, chronic headache forms and cluster headache: a review of their efficacy and tolerability.
Topics: Anticonvulsants; Clinical Trials as Topic; Cluster Headache; Drug Resistance; Fructose; Headache Dis | 2007 |
The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees?
Topics: Animals; Anticonvulsants; beta Catenin; Bipolar Disorder; Brain; Enzyme Inhibitors; Epilepsy; Extrac | 2007 |
GABAergic drugs for the treatment of migraine.
Topics: Acute Disease; Amines; Animals; Cyclohexanecarboxylic Acids; Fructose; GABA Agents; GABA Antagonists | 2007 |
[Comorbidities in migraine patients].
Topics: Adult; Amitriptyline; Analgesics, Non-Narcotic; Anticonvulsants; Anxiety Disorders; Carotid Artery, | 2007 |
Use of intravenous valproic acid for acute migraine.
Topics: Acute Disease; Clinical Trials as Topic; Humans; Injections, Intravenous; Migraine Disorders; Valpro | 2008 |
Therapeutic advances in migraine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Dihydroergotamine; Female; Humans; Indoles; Male; Migraine | 1993 |
The therapeutics of migraine.
Topics: Brain; Humans; Indoles; Migraine Disorders; Neurons; Serotonin Receptor Agonists; Sulfonamides; Suma | 1993 |
Acute and prophylactic treatment of migraine: practical approaches and pharmacologic rationale.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Dihydroergotamine; Ergotamine; Humans; Indoles; Migraine Di | 1993 |
Divalproex sodium in headache: literature review and clinical guidelines.
Topics: Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Headache; Humans; Migraine Disorders | 1996 |
Clinical studies of valproate for migraine prophylaxis.
Topics: Humans; Migraine Disorders; Valproic Acid | 1997 |
Possible mechanisms of valproate in migraine prophylaxis.
Topics: Animals; Central Nervous System; Humans; Migraine Disorders; Valproic Acid | 1997 |
Diagnosis, prophylaxis, and treatment of headaches in the athlete.
Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents, Tricyclic; | 1997 |
[Basilar artery migraine].
Topics: Adolescent; Adult; Anticonvulsants; Basilar Artery; Brain; Child; Child, Preschool; Diagnosis, Diffe | 1997 |
Pharmacological prevention of migraine.
Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Antidepressiv | 1998 |
[Migraine and neurotransmitters].
Topics: GABA Agents; Indoles; Isoindoles; Migraine Disorders; Neurokinin-1 Receptor Antagonists; Neurotransm | 1998 |
Medical treatment of migraine: from mechanisms of action to contraindications.
Topics: Acetaminophen; Adrenergic beta-Antagonists; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Asp | 1998 |
[Valproic acid in prophylactic treatment of migraine].
Topics: Clinical Trials as Topic; Double-Blind Method; GABA Agents; Humans; Migraine Disorders; Treatment Ou | 1998 |
Divalproex sodium--review of prophylactic migraine efficacy, safety and dosage, with recommendations.
Topics: Child; Female; Humans; Male; Migraine Disorders; Pregnancy; Valproic Acid | 1999 |
The impact of pharmacogenetics for migraine.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Calcium Channel Blockers; Calcium Channels; Chromo | 2001 |
Cluster headache: review of the literature.
Topics: Anticonvulsants; Clinical Protocols; Cluster Headache; Diagnosis, Differential; Humans; Migraine Dis | 2001 |
[Treatment of idiopathic headache in childhood - recommendations of the German Migraine and Headache Society (DMKG)].
Topics: Acetaminophen; Adrenergic beta-Antagonists; Age Factors; Analgesics, Non-Narcotic; Biofeedback, Psyc | 2002 |
Modern pharmacotherapy of migraine.
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Chlorpromazine; Dihydroergotamine; Ergotamine; | 1990 |
52 trials available for valproic acid and Migraine Disorders
| Article | Year |
|---|---|
Intravenous ibuprofen versus sodium valproate in acute migraine attacks in the emergency department: A randomized clinical trial.
Topics: Double-Blind Method; Emergency Service, Hospital; Headache; Humans; Ibuprofen; Migraine Disorders; P | 2022 |
Cinnarizine and sodium valproate as the preventive agents of pediatric migraine: A randomized double-blind placebo-controlled trial.
Topics: Adolescent; Calcium Channel Blockers; Child; Cinnarizine; Double-Blind Method; Female; GABA Agents; | 2020 |
Comparative study of magnesium, sodium valproate, and concurrent magnesium-sodium valproate therapy in the prevention of migraine headaches: a randomized controlled double-blind trial.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Humans; Magnesium; Middle Aged; Migraine Disorders; So | 2021 |
Levetiracetam in Compare to Sodium Valproate for Prophylaxis in Chronic Migraine Headache: A Randomized Double-Blind Clinical Trial.
Topics: Adolescent; Adult; Analgesics; Chronic Disease; Disability Evaluation; Double-Blind Method; Female; | 2017 |
Use of melatonin versus valproic acid in prophylaxis of migraine patients: A double-blind randomized clinical trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics; Central Nervous System Agents; Disability Ev | 2017 |
The efficacy of magnesium oxide and sodium valproate in prevention of migraine headache: a randomized, controlled, double-blind, crossover study.
Topics: Adult; Antacids; Anticonvulsants; Cross-Over Studies; Double-Blind Method; Female; Humans; Magnesium | 2021 |
Amitriptyline vs divalproate in migraine prophylaxis: a randomized controlled trial.
Topics: Adolescent; Adult; Amitriptyline; Analgesics, Non-Narcotic; Anticonvulsants; Cohort Studies; Delayed | 2013 |
Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Antimanic Agents; Double-Blind Method; | 2014 |
Sodium valproate in migraine without aura and medication overuse headache: a randomized controlled trial.
Topics: Adolescent; Adult; Age Factors; Analysis of Variance; Antimanic Agents; Disability Evaluation; Doubl | 2014 |
Effect of intravenous sodium valproate vs dexamethasone on acute migraine headache: a double blind randomized clinical trial.
Topics: Acute Disease; Administration, Intravenous; Adult; Chi-Square Distribution; Dexamethasone; Double-Bl | 2015 |
Intravenous Valproate versus Subcutaneous Sumatriptan in Acute Migraine Attack.
Topics: Adult; Female; Humans; Male; Middle Aged; Migraine Disorders; Nausea; Recurrence; Sumatriptan; Valpr | 2015 |
Divalproex extended-release in adolescent migraine prophylaxis: results of a randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Child; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Metho | 2008 |
Effective prophylactic therapy for cyclic vomiting syndrome in children using valproate.
Topics: Anticonvulsants; Child; Child, Preschool; Dehydration; Dose-Response Relationship, Drug; Drug Admini | 2009 |
Safety and tolerability of divalproex sodium extended-release in the prophylaxis of migraine headaches: results of an open-label extension trial in adolescents.
Topics: Adolescent; Child; Delayed-Action Preparations; Double-Blind Method; Female; GABA Agents; Humans; Ma | 2009 |
Divalproex sodium extended-release for the prophylaxis of migraine headache in adolescents: results of a stand-alone, long-term open-label safety study.
Topics: Adolescent; Child; Delayed-Action Preparations; Female; GABA Agents; Humans; Male; Migraine Disorder | 2009 |
Comparison of the effectiveness of topiramate and sodium valproate in pediatric migraine.
Topics: Adolescent; Anticonvulsants; Child; Disability Evaluation; Double-Blind Method; Female; Follow-Up St | 2008 |
Comparison of treatment effect of sodium valproate, propranolol and tricyclic antidepressants in migraine.
Topics: Anticonvulsants; Antidepressive Agents, Tricyclic; Humans; Migraine Disorders; Propranolol; Treatmen | 2009 |
Intravenous sodium valproate aborts migraine headaches rapidly.
Topics: Adult; Female; GABA Agents; Humans; Infusions, Intravenous; Male; Middle Aged; Migraine Disorders; T | 2011 |
A randomized trial of propranolol versus sodium valproate for the prophylaxis of migraine in pediatric patients.
Topics: Adolescent; Child; Child, Preschool; Humans; Migraine Disorders; Propranolol; Time Factors; Valproic | 2010 |
Topiramate vs divalproex sodium in the preventive treatment of migraine: a prospective "real-world" study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Dose-Response Relationship, Drug; Female; Fructose; Humans | 2011 |
A comparative study of the effects of low-dose topiramate versus sodium valproate in migraine prophylaxis.
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fructose; Hum | 2012 |
The effects of cinnarizine versus sodium valproate in migraine prophylaxis.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Calcium Channel Blockers; Cinnarizine; Double-Blind Method | 2013 |
Allodynia in migraine: clinical observation and role of prophylactic therapy.
Topics: Adolescent; Adult; Amitriptyline; Analgesics, Non-Narcotic; Child; Comorbidity; Female; Humans; Hype | 2013 |
Intravenous valproate sodium in the treatment of daily headache.
Topics: Adolescent; Adult; Analgesics; Cerebellar Ataxia; Chronic Disease; Dose-Response Relationship, Drug; | 2002 |
Sodium valproate prophylaxis in childhood migraine.
Topics: Adolescent; Anticonvulsants; Child; Female; Humans; Male; Migraine Disorders; Treatment Outcome; Val | 2002 |
Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticonvulsants; Antiemetics; Double-Blind Method; Emergency | 2003 |
Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticonvulsants; Antiemetics; Double-Blind Method; Emergency | 2003 |
Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticonvulsants; Antiemetics; Double-Blind Method; Emergency | 2003 |
Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticonvulsants; Antiemetics; Double-Blind Method; Emergency | 2003 |
Low dose of sodium divalproate for the treatment of migraine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimanic Agents; Brazil; Drug Administration Schedule; | 2003 |
Treatment of primary headache disorders with intravenous valproate: initial outpatient experience.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Cluster Headache; Female; Headache Disorders; Humans; Infu | 2004 |
Combined therapy for migraine prevention? Clinical experience with a beta-blocker plus sodium valproate in 52 resistant migraine patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Drug Therapy, Combination; Female; Humans; Male; Middle Ag | 2003 |
Comparison of intravenous valproate with intravenous lysine-acetylsalicylic acid in acute migraine attacks.
Topics: Acute Disease; Analgesics; Aspirin; Double-Blind Method; GABA Agents; Humans; Infusions, Intravenous | 2005 |
Effect of divalproex on metabolic parameters is dose related in migraine prophylaxis.
Topics: Adult; Blood Glucose; Body Mass Index; Body Weight; Cholesterol; Dose-Response Relationship, Drug; F | 2005 |
Sodium Valproate versus Propranolol in paediatric migraine prophylaxis.
Topics: Adolescent; Adrenergic beta-Antagonists; Anticonvulsants; Child; Child, Preschool; Humans; Incidence | 2005 |
Comparison of the effect of topiramate and sodium valporate in migraine prevention: a randomized blinded crossover study.
Topics: Adolescent; Adult; Cross-Over Studies; Double-Blind Method; Female; Fructose; GABA Agents; Humans; M | 2006 |
Safety and efficacy of intravenous sodium valproate in the treatment of acute migraine.
Topics: Acute Disease; Adult; Anticonvulsants; Female; Humans; Injections, Intravenous; Middle Aged; Migrain | 2007 |
Subcutaneous histamine versus sodium valproate in migraine prophylaxis: a randomized, controlled, double-blind study.
Topics: Adolescent; Adult; Double-Blind Method; Female; Histamine; Humans; Injections, Subcutaneous; Male; M | 2007 |
Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine.
Topics: Adolescent; Adult; Aged; Botulinum Toxins, Type A; Chronic Disease; Disability Evaluation; Double-Bl | 2008 |
Cinnarizine in refractory migraine prophylaxis: efficacy and tolerability. A comparison with sodium valproate.
Topics: Adolescent; Adult; Calcium Channel Blockers; Cinnarizine; Female; GABA Agents; Humans; Male; Middle | 2008 |
Migraine prophylaxis with divalproex.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders; | 1995 |
Sodium valproate for acute migraine attacks.
Topics: Acute Disease; Adult; Female; Humans; Male; Middle Aged; Migraine Disorders; Valproic Acid | 1994 |
Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study.
Topics: Adult; Female; Headache; Humans; Male; Middle Aged; Migraine Disorders; Muscle Contraction; Placebos | 1994 |
Vestibulo-ocular reflex in migraine patients: the effect of sodium valproate.
Topics: Adult; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders; Reflex, Vestibulo | 1993 |
Sodium valproate in severe migraine and tension-type headache: an open study of long-term efficacy and correlation with blood levels.
Topics: Adult; Anticonvulsants; Female; Follow-Up Studies; Humans; Male; Middle Aged; Migraine Disorders; Pa | 1996 |
Divalproex sodium in migraine prophylaxis: a dose-controlled study.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Age | 1997 |
A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without aura.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Cross-Over Studies; Female; GABA Agents; Human | 1997 |
Prophylactic sodium valproate therapy in patients with drug-resistant migraine.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle | 1998 |
The efficacy of divalproex sodium in the prophylactic treatment of children with migraine.
Topics: Adolescent; Child; Female; GABA Agents; Humans; Male; Migraine Disorders; Treatment Outcome; Valproi | 2000 |
Intravenous valproate sodium (depacon) aborts migraine rapidly: a preliminary report.
Topics: Acute Disease; Adolescent; Adult; Female; GABA Agents; Humans; Infusions, Intravenous; Male; Middle | 2000 |
Valproic acid is effective in migraine prophylaxis at low serum levels: a prospective open-label study.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Migraine Disor | 2001 |
Visual cortex excitability in migraine before and after valproate prophylaxis: a pilot study using TMS.
Topics: Anticonvulsants; Electromagnetic Fields; gamma-Aminobutyric Acid; Humans; Longitudinal Studies; Migr | 2002 |
A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis.
Topics: Adolescent; Adult; Aged; Delayed-Action Preparations; Double-Blind Method; Female; GABA Agents; Huma | 2002 |
Effect of sodium valproate on the secretion of prolactin, cortisol and growth hormone in migraine patients.
Topics: Adult; Female; Growth Hormone; Humans; Hydrocortisone; Male; Middle Aged; Migraine Disorders; Prolac | 1992 |
Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo.
Topics: Adolescent; Adult; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders; Valpr | 1992 |
99 other studies available for valproic acid and Migraine Disorders
| Article | Year |
|---|---|
Valproate prescription to women of childbearing age in English primary care: repeated cross-sectional analyses and retrospective cohort study.
Topics: Adolescent; Adult; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Cohort Studies; Contraceptio | 2022 |
Fremanezumab in individuals with chronic migraine who had inadequate response to onabotulinumtoxinA and topiramate or valproic acid.
Topics: Antibodies, Monoclonal; Botulinum Toxins, Type A; Chronic Disease; Double-Blind Method; Humans; Migr | 2022 |
The implementation of transcranial Doppler ultrasonography for preclinical study of migraine.
Topics: Animals; Blood Flow Velocity; Cerebrovascular Circulation; Humans; Migraine Disorders; Rats; Reprodu | 2022 |
Levetiracetam in the prophylactic treatment of episodic migraine: A prospective open label study.
Topics: Adult; Anticonvulsants; Double-Blind Method; Humans; Levetiracetam; Migraine Disorders; Migraine wit | 2022 |
Intravenous ibuprofen versus sodium valproate in acute migraine attacks in the emergency department.
Topics: Anticonvulsants; Double-Blind Method; Emergency Service, Hospital; Humans; Ibuprofen; Migraine Disor | 2022 |
Intravenous ibuprofen versus sodium valproate in acute migraine attacks in the emergency department.
Topics: Anticonvulsants; Double-Blind Method; Emergency Service, Hospital; Humans; Ibuprofen; Migraine Disor | 2023 |
Genome-wide DNA methylation analysis in an antimigraine-treated preclinical model of cortical spreading depolarization.
Topics: Animals; Cortical Spreading Depression; DNA Methylation; Migraine Disorders; Rats; Rats, Sprague-Daw | 2023 |
Comprehensive Migraine Initiative in the Pediatric Emergency Department Improves Treatment Outcomes.
Topics: Adolescent; Clinical Protocols; Emergency Service, Hospital; Female; Humans; Ketorolac; Magnesium Su | 2020 |
Consensus of the Hellenic Headache Society on the diagnosis and treatment of migraine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Botulinum Toxins, Type A; Consensus | 2019 |
[Confusional migraine in a young adult female: Is it a subtype of migraine with aura?]
Topics: Adult; Epilepsy; Female; Humans; Migraine Disorders; Topiramate; Valproic Acid; Young Adult | 2020 |
Retrospective Chart Review of Intravenous Valproate Sodium as a Preventive Treatment for Patients With Chronic Migraine.
Topics: Administration, Intravenous; Adult; Aged; Anticonvulsants; Female; Humans; Male; Middle Aged; Migrai | 2020 |
Sodium valproate in paediatric migraine.
Topics: Child; Cinnarizine; Double-Blind Method; Humans; Migraine Disorders; Propranolol; Valproic Acid | 2020 |
The use of anti-epileptic drugs in prevention of migraine in children and adolescents.
Topics: Adolescent; Child; Cinnarizine; Double-Blind Method; Humans; Migraine Disorders; Valproic Acid | 2020 |
Serotonin syndrome in patients with headache disorders.
Topics: Acetaminophen; Adult; Amitriptyline; Analgesics; Cluster Headache; Drug Therapy, Combination; Flunar | 2017 |
Valproate Plays a Protective Role against Migraine by Inhibiting Protein Kinase C Signalling in Nitroglycerin-treated Mice.
Topics: Animals; Dura Mater; Enzyme Inhibitors; Injections, Intraperitoneal; Isoenzymes; Male; Mice, Inbred | 2018 |
Utilization of Antiepileptic Medicines in Swedish Children and Adolescents with Different Diagnoses.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Drug Prescriptions; Drug Utilization; Epilepsy | 2018 |
Continuous Intravenous Valproate as Abortive Therapy for Pediatric Status Migrainosus.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Female; Humans; Infusions, Intravenous; Male; | 2018 |
[Prescribing valproate to girls and women of childbearing age in Germany : Analysis of trends based on claims data].
Topics: Adult; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Drug Prescriptions; Drug Utilization; Ep | 2018 |
Latest clinical recommendations on valproate use for migraine prophylaxis in women of childbearing age: overview from European Medicines Agency and European Headache Federation.
Topics: Adult; Female; GABA Agents; Humans; Migraine Disorders; Risk; Valproic Acid | 2018 |
Antiepileptic Drug Treatment Patterns in Women of Childbearing Age With Epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Anxiety Disorders; Comorbidity; Dissociative Disorders; Epilepsi | 2019 |
Treatment effects and comorbid diseases in 58 patients with visual snow.
Topics: Anticonvulsants; Humans; Migraine Disorders; Neurologists; Snow; Valproic Acid | 2019 |
Sodium Divalproate in Low Alternating Daily Doses for Migraine Prevention: A Retrospective Study.
Topics: Adolescent; Adult; Female; GABA Agents; Humans; Male; Middle Aged; Migraine Disorders; Retrospective | 2019 |
In brief: warning against use of valproate for migraine prevention during pregnancy.
Topics: Anticonvulsants; Child; Child Development; Child, Preschool; Female; Humans; Intelligence; Intellige | 2013 |
Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Antimanic Agents; Female; Humans; Ketorolac; M | 2014 |
Author response.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Antimanic Agents; Female; Humans; Ketorolac; M | 2014 |
Author response.
Topics: Authorship; Humans; Ketorolac; Metoclopramide; Migraine Disorders; Valproic Acid | 2014 |
Intravenous Sodium Valproate for Acute Pediatric Headache.
Topics: Acute Disease; Administration, Intravenous; Adolescent; Child; Emergency Service, Hospital; Enzyme I | 2015 |
HDAC3 role in medication consumption in medication overuse headache patients: a pilot study.
Topics: Adult; Female; Genetic Association Studies; Headache Disorders, Secondary; High-Throughput Nucleotid | 2015 |
sec-Butylpropylacetamide (SPD) has antimigraine properties.
Topics: Amides; Animals; Anticonvulsants; Cell Line, Tumor; Cells, Cultured; Cerebral Cortex; Cortical Sprea | 2016 |
Cerebral reactivity in migraine patients measured with functional near-infrared spectroscopy.
Topics: Adult; Analgesics, Non-Narcotic; Cerebrovascular Circulation; Dihydroergotamine; Female; Humans; Mag | 2015 |
The effects of acute and preventive migraine therapies in a mouse model of chronic migraine.
Topics: Acute Disease; Amiloride; Animals; Anticonvulsants; Disease Models, Animal; Drug Evaluation, Preclin | 2016 |
Pharmacokinetics and Clinical Utility of Valproic Acid Administered via Continuous Infusion.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Child; Child, Preschool; Cohort Studies | 2016 |
Auditory hallucinations preceding migraine, differentiation with epileptic origin: A case report.
Topics: Adult; Anticonvulsants; Brain; Diagnosis, Differential; Epilepsy; Follow-Up Studies; Hallucinations; | 2016 |
Should women of childbearing potential be prescribed valproate? a call to action.
Topics: Abnormalities, Drug-Induced; Bipolar Disorder; Contraception Behavior; Epilepsy; Female; Humans; Inf | 2016 |
Valproate ameliorates nitroglycerin-induced migraine in trigeminal nucleus caudalis in rats through inhibition of NF-кB.
Topics: Animals; Blotting, Western; Calcitonin Gene-Related Peptide; Disease Models, Animal; Down-Regulation | 2016 |
Association of MDR1, CYP2D6, and CYP2C19 gene polymorphisms with prophylactic migraine treatment response.
Topics: Adult; Amitriptyline; ATP Binding Cassette Transporter, Subfamily B; Central Nervous System Agents; | 2016 |
Hemiplegic migraine and late-onset photosensitive epileptic seizures.
Topics: Adult; Anticonvulsants; Electroencephalography; Epilepsy, Reflex; Female; Glycosides; Humans; Migrai | 2016 |
Valproate Attenuates Nitroglycerin-Induced Trigeminovascular Activation by Preserving Mitochondrial Function in a Rat Model of Migraine.
Topics: Animals; DNA-Binding Proteins; DNA, Mitochondrial; Male; Membrane Potential, Mitochondrial; Migraine | 2016 |
Using a graphical risk tool to examine willingness to take migraine prophylactic medications.
Topics: Amines; Analgesics; Antidepressive Agents; Antihypertensive Agents; Cross-Sectional Studies; Cyclohe | 2016 |
Valproate for Adult Migraine Prophylaxis.
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Female; Humans; Male; Migraine Disorders; | 2016 |
Antiepileptic drugs in migraine and epilepsy: Who is at increased risk of adverse events?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Child; Epilepsy; Female; Humans; Lamotr | 2018 |
Persistence with migraine prophylactic treatment and acute migraine medication utilization in the managed care setting.
Topics: Adult; Age Factors; Amitriptyline; Cohort Studies; Databases, Factual; Dose-Response Relationship, D | 2008 |
Valproic acid delayed release (Stavzor).
Topics: Anticonvulsants; Capsules; Chemistry, Pharmaceutical; Delayed-Action Preparations; Epilepsy; Humans; | 2009 |
Migraine, valproic acid, and lipoprotein(a).
Topics: Analgesics; Child; Humans; Lipoprotein(a); Migraine Disorders; Risk Factors; Stroke; Valproic Acid | 2009 |
Migrainous vertigo responsive to intravenous methylprednisolone: case reports.
Topics: Adult; Anti-Inflammatory Agents; Anticonvulsants; Female; Humans; Injections, Intravenous; Male; Met | 2009 |
GABA and valproate modulate trigeminovascular nociceptive transmission in the thalamus.
Topics: Amines; Animals; Anticonvulsants; Cerebral Arteries; Cyclohexanecarboxylic Acids; Disease Models, An | 2010 |
Neurostabilizers for migraine prevention. From dosage administration to patient expectations.
Topics: Dose-Response Relationship, Drug; Fructose; GABA Agents; Humans; Migraine Disorders; Neuroprotective | 2007 |
Acute confusional migraine in an adolescent: response to intravenous valproate.
Topics: Child; Diagnosis, Differential; Female; Hematoma, Subdural, Acute; Humans; Injections, Intravenous; | 2010 |
Pharmacological prophylaxis of chronic migraine: a review of double-blind placebo-controlled trials.
Topics: Amines; Analgesics; Chronic Disease; Clonidine; Cyclohexanecarboxylic Acids; Diagnosis, Differential | 2010 |
Gastaut type-idiopathic childhood occipital epilepsy and childhood absence epilepsy: a clinically significant association?
Topics: Anticonvulsants; Blindness; Child; Electroencephalography; Epilepsy; Epilepsy, Absence; Ethosuximide | 2010 |
Profile of children with migraine.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Female; Flunarizine; Fructose; Humans; Male; M | 2010 |
Migraine preventive drugs differentially affect cortical spreading depression in rat.
Topics: Animals; Anticonvulsants; Cortical Spreading Depression; Lamotrigine; Male; Migraine Disorders; Rats | 2011 |
Oxcarbazepine does not suppress cortical spreading depression.
Topics: Animals; Anticonvulsants; Brain; Carbamazepine; Cortical Spreading Depression; Electric Stimulation; | 2011 |
Low-dose topiramate plus sodium divalproate for positive responders intolerant to full-dose monotherapy.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Dose-Response Relationship, Drug; Drug Adm | 2012 |
[Chronic migraine: not well known but not rare!].
Topics: Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Chronic Disease; Femal | 2011 |
Subclinical rhythmic electrographic discharges of adults in a patient with migraine.
Topics: Brain Waves; Electroencephalography; Female; GABA Agents; Humans; Middle Aged; Migraine Disorders; V | 2012 |
Drugs to prevent migraines are underused.
Topics: Adrenergic beta-Antagonists; Anticonvulsants; Fructose; Humans; Migraine Disorders; Preventive Healt | 2012 |
Migraine prevention: techniques are available, but underutilized. New guidelines emphasize ways to reduce the number of migraine attacks.
Topics: Adrenergic beta-Antagonists; Anticonvulsants; Fructose; Humans; Migraine Disorders; Practice Guideli | 2012 |
Topiramate-valproate-induced encephalopathy in migraine.
Topics: Adult; Analgesics; Drug Therapy, Combination; Encephalitis; Fructose; Humans; Male; Migraine Disorde | 2012 |
Behavior in the open field predicts the number of KCl-induced cortical spreading depressions in rats.
Topics: Animals; Antimanic Agents; Anxiety; Behavior, Animal; Cortical Spreading Depression; Electrodes, Imp | 2013 |
Reversible CT perfusion abnormalities in patient with migraine variant: a two phase process.
Topics: Anti-Inflammatory Agents; Aphasia; Blood Volume; Cerebral Angiography; Cerebrovascular Circulation; | 2013 |
Valproic acid in migraine prophylaxis of young patients. Three new reports.
Topics: Adolescent; Child; Humans; Male; Migraine Disorders; Valproic Acid | 2002 |
Migraine preventive medication reduces resource utilization.
Topics: Amitriptyline; Cohort Studies; Health Resources; Humans; Migraine Disorders; Practice Guidelines as | 2003 |
Complex cardiac defect with hypoplastic right ventricle in a fetus with valproate exposure.
Topics: Abortion, Induced; Adult; Anticonvulsants; Diagnosis, Differential; Epilepsy; Female; Heart Defects, | 2005 |
Bending the rule of monotherapy for migraine prevention?
Topics: Adrenergic beta-Antagonists; Adult; Amitriptyline; Drug Therapy, Combination; Female; Humans; Migrai | 2005 |
[Migraine therapy].
Topics: Adrenergic beta-Antagonists; Fructose; Germany; Humans; Migraine Disorders; Practice Guidelines as T | 2006 |
Pharmacological prevention of migraine: to be considered case by case.
Topics: Adrenergic beta-Antagonists; Amitriptyline; Anticonvulsants; Antidepressive Agents; Cost-Benefit Ana | 2006 |
Clinical utility of a continuous intravenous infusion of valproic acid in pediatric patients.
Topics: Administration, Oral; Adolescent; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combinatio | 2007 |
An adult case of cyclic vomiting syndrome successfully responding to valproic acid.
Topics: Anti-Anxiety Agents; Anticonvulsants; Antiemetics; Consciousness Disorders; Diazepam; Female; Humans | 2008 |
The valproate mechanisms of action in migraine.
Topics: Humans; Migraine Disorders; Valproic Acid | 1994 |
Anti-migraine compounds fail to modulate the propagation of cortical spreading depression in the cat.
Topics: Analgesics; Animals; Aspirin; Cats; Cerebral Cortex; Clonazepam; Cortical Spreading Depression; Dihy | 1994 |
Valproate in intractable headache.
Topics: Brain; Chronic Disease; Headache; Humans; Migraine Disorders; Neurons; Valproic Acid | 1994 |
A differential response to treatment with divalproex sodium in patients with intractable headache.
Topics: Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Fo | 1994 |
Divalproex sodium: migraine treatment and monitoring.
Topics: Adolescent; Adult; Age Factors; Child; Child, Preschool; Humans; Infant; Infant, Newborn; Liver; Liv | 1996 |
High-dose versus low-dose valproic acid as a prophylactic medication.
Topics: Adult; Chronic Disease; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; GABA Age | 1996 |
Successful treatment of persistent migraine aura with divalproex sodium.
Topics: Female; Humans; Middle Aged; Migraine Disorders; Sensation Disorders; Valproic Acid | 1997 |
Valproate and lamotrigine in migraine.
Topics: Calcium Channel Blockers; Humans; Lamotrigine; Migraine Disorders; Triazines; Valproic Acid | 1997 |
Multiorgan system failure caused by valproic acid toxicity.
Topics: Acute Kidney Injury; Anticonvulsants; Emergencies; Humans; Liver Failure; Male; Middle Aged; Migrain | 1997 |
Migraine relief.
Topics: GABA Agents; Humans; Migraine Disorders; Sumatriptan; Valproic Acid; Vasoconstrictor Agents | 1997 |
Relief for migraine sufferers.
Topics: GABA Agents; Humans; Migraine Disorders; Sumatriptan; Valproic Acid; Vasoconstrictor Agents | 1998 |
Migraine with visual aura and photosensitive epileptic seizures.
Topics: Adult; Comorbidity; Cortical Spreading Depression; Dopamine; Electroencephalography; Epilepsy; Human | 1997 |
New "triptans" and other drugs for migraine.
Topics: Adrenergic beta-Antagonists; Amitriptyline; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive | 1998 |
Abdominal epilepsy in an adolescent with bilateral perisylvian polymicrogyria.
Topics: Abdominal Pain; Adolescent; Adult; Cerebral Cortex; Electroencephalography; Epilepsy, Temporal Lobe; | 1998 |
Migraine polypharmacy and the tolerability of sumatriptan: a large-scale, prospective study.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Anti-As | 1999 |
An analysis of the "carry-over effect" following successful short-term treatment of transformed migraine with divalproex sodium.
Topics: Adolescent; Adult; Aged; Female; Humans; Male; Middle Aged; Migraine Disorders; Prospective Studies; | 2000 |
Valproate prophylaxis for migraine induced by selective serotonin reuptake inhibitors.
Topics: Adult; Drug Therapy, Combination; Female; GABA Agents; Humans; Migraine Disorders; Oxazepam; Selecti | 2000 |
Migraine-associated seizure: a case of reversible MRI abnormalities and persistent nondominant hemisphere syndrome.
Topics: Anticonvulsants; Brain; Epilepsy, Generalized; Female; Humans; Magnetic Resonance Imaging; Middle Ag | 2000 |
Different effects of GABAergic anticonvulsants on 4-aminopyridine-induced spontaneous GABAergic hyperpolarizations of hippocampal pyramidal cells--implication for their potency in migraine therapy.
Topics: 4-Aminopyridine; Acetates; Amines; Analgesics; Animals; Anticonvulsants; Convulsants; Cyclohexanecar | 2000 |
Cortical hyperexcitability is cortical under-inhibition: evidence from a novel functional test of migraine patients.
Topics: Adult; Aged; Analgesics; Cortical Spreading Depression; Female; GABA-A Receptor Agonists; gamma-Amin | 2000 |
Use of intravenous valproate sodium in status migraine.
Topics: Acute Disease; Adult; Female; Humans; Infusions, Intravenous; Migraine Disorders; Nausea; Pain, Intr | 2000 |
Divalproex in the long-term treatment of chronic daily headache.
Topics: Adult; Body Weight; Female; Headache Disorders; Humans; Male; Migraine Disorders; Retrospective Stud | 2001 |
Safety of divalproex sodium in migraine prophylaxis: an open-label, long-term study. Long-term Safety of Depakote in Headache Prophylaxis Study Group.
Topics: Adult; Aged; Female; GABA Agents; Humans; Longitudinal Studies; Male; Middle Aged; Migraine Disorder | 1999 |
Dubious about Depakote.
Topics: Humans; Migraine Disorders; Valproic Acid | 2001 |
Pediatric migraine prophylaxis with divalproex.
Topics: Adolescent; Child; Epilepsy, Generalized; Epilepsy, Rolandic; Female; Humans; Male; Mental Disorders | 2001 |
[Migraine: a disease, not a symptom].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Analgesics; Analgesics, Non-Narcotic; Ant | 2002 |
Divalproex sodium in the treatment of migraine and cluster headaches.
Topics: Cluster Headache; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up | 2002 |
Extended-release divalproex sodium improves the quality of life of adolescent migraineurs.
Topics: Adolescent; Adult; Anticonvulsants; Child; Delayed-Action Preparations; Humans; Male; Migraine Disor | 2002 |
Valproate in the prophylaxis of migraine.
Topics: Humans; Migraine Disorders; Valproic Acid | 1992 |
Valproate: a new drug in migraine prophylaxis.
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Male; Middle Aged; Migraine Disorders; Prospective S | 1988 |